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2 ABBREVIATIONS 
 
 
AGES Age Gender Extent Size 
AMES Age Metastasis Extent Size 
BRAF B isoform of RAF kinase  
DTC Differentiated thyroid cancer  
DxWBS Diagnostic whole-body scan  
FNAB Fine-needle aspiration biopsy 
FTC Follicular thyroid cancer  
GBq Giga-Bequerel (109  Bequerel) 
HRQoL Health-related quality of life 
HUCH Helsinki University Central Hospital 
MACIS Metastasis Age Completeness of resection Invasion Size 
MMP Matrix metalloproteinase 
NCCN National Comprehensive Cancer Network 
NIS sodium-iodine symporter 
PET Positron emission tomography 
PTC Papillary thyroid cancer 
RAI Radio-active iodine 
rhTSH Recombinant human TSH 
RRA Radio-active iodine thyroid remnant ablation 
RxWBS Post-treatment whole-body scan 
TG Thyroglobulin  
TNM Tumour Node Metastasis 
TSH Thyroid-stimulating hormone or thyrotropin 
TTE Total thyroidectomy 
UICC Union Internationale Contre le Cancer (International Union Against Cancer) 
US Ultrasonography 
VEGF Vascular endothelial growth factor 
WBS Whole-body scan  
WDTC Well-differentiated thyroid cancer 
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3 ABSTRACT 
 
 
The goal of initial therapy in differentiated thyroid cancer (DTC) is to minimize 
disease related mortality and morbidity by surgically removing the primary tumour 
and all metastasized tumour tissue. A second goal is to minimize risk of recurrence 
and metastatic spread by facilitating post-operative radio-iodine ablation (RRA), 
permitting accurate long-term surveillance. Recurrences are relatively common even 
in patient population at low-risk for cancer-specific death, occurring in 10-40% of 
cases. The treatment and follow-up schemes have varied between centres and there 
is ongoing debate about appropriate methods for primary therapy and surveillance. 
With the increasing incidence of DTC, the need for new factors prognostic of disease 
recurrence is growing; most of the prognostic systems have been validated with 
cancer-specific death as outcome. 
 
We designed an observational retrospective study to assess the outcome of a large 
cohort of patients with low-risk thyroid carcinoma and with a uniform primary 
therapy. All patients belong to TNM stage I or II and were considered disease-free 
after initial therapy. We evaluated the safety and efficacy of a surveillance paradigm, 
comprising yearly thyroglobulin (TG) measurements on L-T4 therapy and neck 
ultrasonography (US) every second year, with an increase in TG to a detectable level 
being an indication for further investigations. We examined the health-related quality 
of life (HRQoL) of the patient cohort after long-term follow-up using a validated 
multidimensional method (15D®).   
 
We studied factors correlating with disease recurrence, including patient 
demographics, tumour characteristics and parameters with primary therapy, in 495 
low-risk patients treated at Helsinki University Central Hospital over a 15-year period. 
Post-operative and post-ablative TG concentrations, age, tumour size, local 
infiltration and nodal metastasis at primary surgery, number of neck US, fine-needle 
aspiration biopsies (FNABs) and operations performed, presence of BRAF mutation 
in papillary tumour tissue, disease recurrences and cancer-specific deaths were 
evaluated.  
 
The majority of patients had total thyroidectomy and radio-active iodine remnant 
ablation as initial treatment. The median follow-up was 16 (range 10–24) years. Fifty-
one patients (10.3%) experienced disease recurrence during follow-up. A combination 
of neck US and high TG revealed most recurrences.  
 
In multiple logistic regression analysis, post-ablative measurable TG concentrations 
(odds ratio (OR) 3.72, confidence interval (CI) 1.71–8.05, P = 0.0009) and presence of 
local infiltration on primary surgery (OR 2.66, CI 1.03–6.90, P = 0.04) were the only 
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independent predictors of recurrence. BRAF V600E mutation is common (prevalence 
67%) in this low-risk papillary thyroid cancer patient group but does not predict 
recurrence after long-term follow-up after initial treatment with total thyroidectomy 
(TTE) and RRA. 
 
HRQoL was preserved in DTC patients compared to a large age- and gender-
standardized sample of the general Finnish population (n = 6001).  After long-term 
follow-up, overall HRQoL is comparable with that of the general population. DTC 
patients demonstrate an age-related decline in HRQoL, similar to that seen in the 
population in general. 
 
We conclude that post-ablative TG concentration is a strong predictor of disease 
recurrence in DTC.  Although longer follow-up is needed, monitoring low-risk 
differentiated thyroid carcinoma patients with neck US and TG measured on L-T4 
appears safe and effective. 
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4 INTRODUCTION 
 
 
Primary thyroid carcinoma is not a single disease, but is a heterogenic group of 
conditions with a wide variation in behavior and prognosis; both the most indolent 
and most aggressive of malignant tumours are of thyroid origin.  Among the 
generally treatable thyroid tumours are papillary and follicular carcinomas, 
designated “differentiated thyroid carcinoma”, or DTC, together with medullary 
carcinoma. Papillary and follicular carcinomas account for the majority of thyroid 
carcinomas (85 - 95%) and are of follicular cell origin (Schlumberger 1998). These are 
well differentiated, treatable and often have little effect on the patients´ life 
expectancy.   
 
Differentiated thyroid carcinomas are today generally being diagnosed at an earlier 
stage (Davies and Welch 2006, Kent et al. 2007), which has resulted in the need to 
adapt the treatment and follow-up strategies to a less aggressive disease. The 
diagnostic procedure is formed and characterized by the very widespread use of 
ultrasonography (US) and US-guided fine-needle aspiration biopsies (FNABs). 
Thyroidectomy remains the cornerstone of initial treatment of DTC, but the post-
operative administration of radio-iodine ablative therapy is considered most 
beneficial for patients at a higher risk of thyroid cancer-related death (Cooper et al. 
2006, Cooper et al. 2009, Sacks et al. 2010).  Despite general treatability and early 
potential to be cured, even the most indolent thyroid cancers have the potential to 
recur as late as decades after primary therapy.  Thus, the main goal for follow-up is to 
detect recurrent or persistent disease at the earliest stage possible, while 
simultaneously avoiding unnecessary tests for the patient and unnecessary costs for 
health care units. A number of prognostic scoring systems based on independent 
prognostic factors have been developed; however, most of these systems were 
validated using cancer-specific survival as the outcome (Cady and Rossi 1988, Hay et 
al. 1993). Since the majority of DTC patients are at a low-risk for cancer death, novel 
factors prognostic of disease recurrence are needed to guide the clinician today.  
 
Due to the relative infrequency, indolence and long natural course of papillary and 
follicular DTC, most of the management strategies have been based on large 
retrospective studies and on consensus opinions of experts. At Helsinki University 
Central Hospital (HUCH), treatment and surveillance of low-risk DTC patients have 
already for two decades been carried out according to a uniform protocol much in 
the manner now discussed in and adapted by the international literature.  
 
The aims of this work were to investigate retrospectively whether the treatment and 
especially the surveillance scheme in HUCH have succeeded in providing safe and 
efficient care for DTC patients. We analysed the long-term outcome of a large cohort 
of 495 DTC patients at low-risk of cancer-specific death, uniformly treated at one 
institution. The initial treatment consisting of near-total thyroidectomy and post-
 12 
 
operative radio-iodine ablation can be seen as active and in light of the current shift 
of treatment towards a more selective use of radio-iodine (RAI), as rather aggressive. 
The current work adds to the discussion of how to best balance benefits and harms 
in the use of RAI.  With the increasing incidence and prevalence of DTC, the number 
of patients needing long-term follow-up is growing. Another important goal of this 
work has been to find novel prognostic factors for disease recurrence in low-risk DTC 
to guide surveillance in the future. 
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5 REVIEW OF THE LITERATURE 
 
 
5.1  Histopathology of differentiated thyroid carcinoma 
 
The normal thyroid gland weighs about 15−20 g and is macroscopically composed of 
two lobes connected by the isthmus. Each lobe can be regarded as an independent 
entity due to ipsilateral blood supply and lymph drainage. The basic cellular unit of 
the thyroid is the follicle, which is lined with epithelial cells (follicular cells) and filled 
with a colloid.  Epithelial neoplasms arising from these follicular cells include benign 
follicular adenomas, malignant follicular carcinomas, papillary carcinomas and 
undifferentiated and anaplastic carcinomas. The calcitonin (CT) -producing 
parafollicular cells or C-cells account for only about 0.1% of all thyroid cells and are the 
origin of medullary carcinomas. The stroma between follicles is highly vascular.  
 
5.1.1 Papillary thyroid carcinoma 
 
Papillary thyroid carcinoma (PTC) is macroscopically a firm tumour that is 
unencapsulated or partly encapsulated (Hay 1990). PTC may be cystic or partly 
necrotic, and extension beyond the thyroid capsule is reported in about 8 - 30% of 
cases. PTC is also often multifocal in a single lobe and is bilateral in up to 60% of cases 
(Cooper et al. 2006). Characteristic microscopic findings are papillary structures lined 
with a single layer of epithelial cells.  Pathognomic to PTC are psammoma bodies, 
calcified structures in the core of papillae. The nuclei of PTC cells are large and 
overlapping with irregular borders. This distinctive appearance of “ground glass 
nuclei” permits the diagnosis also from cytological material. PTCs invade the 
lymphatic vessels early in the course of the disease, and lymphatic metastases are 
found in 20 - 80% of cases at diagnosis, depending on the extent of lymph-node 
dissection and examination of surgical material. Vascular invasion is rare and distant 
metastases (in 5 - 10% of cases) are allegedly mostly the result of lymphatic spread. 
Lungs are the predominant site of distant metastasis in PTC, but involvement of 
bone, soft tissue, liver and occasionally the brain are also seen.  
 
 
5.1.2 Variants of papillary thyroid carcinoma 
 
The World Health Organization (WHO) defines papillary thyroid microcarcinoma 
(PTM) as PTC measuring up to 1.0 cm in diameter.  The incidence of PTM in autopsy 
material ranges from 4% to 36% (Harach et al. 1985, Hay 1990). The encapsulated 
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variant of PTC is characterized by a tumour capsule but local invasion. Both of these 
variants carry a very good prognosis.  
 
In the follicular variant of PTC, follicles are predominant over papillae but carry the 
same nuclear features as classical PTC. This variant is more frequently found in 
younger patients and was detected in 20% of the post-exposion childhood thyroid 
cancers after the Chernobyl nuclear accident (Furmanchuk et al. 1992). 
 
Occurring at a younger age, the diffuse sclerosing variant constitutes 2% of papillary 
carcinomas. Diffuse involvement of one or both lobes occurs with sclerosis, patchy 
widespread lymphocytic infiltration and abundant psammoma bodies (Soares et al. 
1989). Lymph node metastases are almost always present and lung metastases often 
occur.  
 
The tall cell variant occurs mostly in elderly patients and is characterized by large size, 
vascular invasion and frequent metastasis. Microscopically, it presents with well-
formed papillae covered with tall cells.  
 
The columnar cell variant is rare and presents with intrathyroidal metastasis.  Papillary 
carcinoma with squamous cell or mucoepidermoid carcinoma is a rare, combined form 
of PTC, usually with an aggressive clinical course. 
 
5.1.3 Follicular thyroid carcinoma 
 
Follicular thyroid carcinoma (FTC) is defined as a malignant epithelial tumour with 
follicular differentiation, but no diagnostic features of PTC. FTC is less frequent than 
PTC and usually presents as a solitary tumour. Microscopically, FTC may appear as 
well-formed follicles or solid growth. Capsular and/or vascular invasion confirms the 
malignant nature and is the basis for diagnosis. Confirmation with a needle biopsy 
specimen is impossible, and thus, a histological sample is always needed to diagnose 
FTC. FTC is usually divided into two categories with different prognosis according to 
the degree of invasiveness; minimally or widely invasive. FTC readily invades blood 
vessels and only rarely lymphatic vessels, and distant metastases are seen in lungs, 
bone and brain.  
 
5.1.4 Variants of follicular thyroid carcinoma 
 
Clear cell carcinoma is a rare variant of FTC, with clinical behaviour similar to classic 
FTC.  
 
The oxyphilic variant of FTC (Hürthle cell) occurs mainly in elderly patients and 
presents with cells with oncocytic features. Macroscopically, it presents as a solitary 
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tumour with potential for extrathyroid extension and both lymph node and distant 
metastases.  
 
Poorly differentiated FTC is an intermediate group of tumours between differentiated 
and anaplastic carcinomas with a characteristic histological picture of small cells and 
solid growth with patches of necrosis and vascular invasion. 
 
 
5.2  Epidemiology 
 
Although thyroid carcinoma only accounts for 1% of all malignancies, it is the most 
common endocrine tumour (Davies and Welch 2006). The annual incidence of 
thyroid cancer per million inhabitants differs widely between countries and ranges 
from 12 to 40 in men and from 20 to 50 in women. The lowest incidence rates have 
been reported in Denmark and the Netherlands and the highest in France, Japan and 
the USA.  In USA, there has been a 2.4-fold increase in the incidence of thyroid 
cancer, from 3.6 per 100 000 in 1973 to 8.7 per 100 000 in 2002 (Davies and Welch 
2006, Kent et al. 2007). The increasing incidence of all thyroid cancers in Finland 
between 1964 and 2010 is illustrated in Figure 1 (data from the Finnish Cancer 
Registry).  
 
 
 
Figure 1.Incidence of thyroid cancer in Finland in 1964-2010 
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The increase has been attributed to the rising incidence of particularly small low-risk 
DTC (Davies and Welch 2006, Kent et al. 2007). In an analysis of 4817 patients treated 
for DTC in one institution between 1969 and 2004, there was a significant increase in 
small tumours (< 1 cm) diagnosed between 1969 to 1989 and 1990 to 2004 (7.9% vs. 
28.7% of all, respectively, p<0.0001) (Elisei et al. 2010). A significant decrease in the 
prevalence of both nodal (34.2% vs. 22.4%) and distant metastasis (5.4% vs. 2%) was 
also observed (Elisei et al. 2010). A registry-based study of 7422 thyroid cancer cases 
revealed a significant increase in small non-palpable tumours between 1990 and 2001 
(Kent et al. 2007).  
 
However, also recently, an increased incidence of all sizes of thyroid tumours has 
been reported in the United States. In 1988–2005, a significant increase was also 
observed for tumours >4 cm among men and women (Chen et al. 2009). These data 
indicate that increased diagnostic scrutiny is not the only explanation for this 
increase, but environmental influence should also be considered. 
 
Tumours most often occur in individuals aged 20-50 years. The mean age at diagnosis 
for papillary cancer is slightly lower than for follicular cancer (mid-40s to early 50s 
and 50s, respectively). In adults, the female-to-male ratio of clinically diagnosed 
papillary carcinoma is 4:1 to 3:1 (Kent et al. 2007, Elisei et al. 2010).  
 
 
5.3 Aetiology and pathogenesis 
 
The aetiology of DTC is largely unknown. A higher risk for differentiated thyroid 
carcinoma correlates with a number of genetic disorders. A 4- to 10-fold increased 
risk of thyroid cancer in first-degree relatives of patients with thyroid cancer 
suggests a genetic basis for these tumours (Malchoff and Malchoff 2002). A familial 
predisposition for PTC has been supported by epidemiological studies (Galanti et al. 
1997, Hemminki and Dong 2000). Also, a parallel incidence has been described in 
monozygotic twins (Malchoff and Malchoff 2002). A number of familial syndromes 
with an increased risk for PTC are known, among them familial adenomatous 
polyposis and its subtype Gardner’s syndrome, which are caused by inherited 
mutations of a tumour suppressor gene (Giardiello et al. 1993, Malchoff and Malchoff 
2002). A correlation between papillary thyroid carcinoma and some types of human 
leukocyte antigen (HLA) has also been observed (Porto et al. 2006).  
 
5.3.1 Ionizing radiation 
 
Ionizing radiation is the only known external predisposing factor for thyroid cancer. 
External radiation to the neck increases the incidence of papillary carcinoma of the 
thyroid later in life, and irradiation during childhood has been associated with the 
greatest risk for acquiring papillary thyroid cancer (Ron et al. 1995).  
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Recently, data have become available from studies of over 4000 people who 
developed thyroid cancer after the Chernobyl nuclear accident in 1986 (Nikiforov 
2006). They have revealed that radiation exposure during childhood carries an 
increased risk of thyroid cancer and that the risk is radiation dose-dependent. As 
many as 9% of children with radiation exposure have developed thyroid cancer over a 
period of 20 years (Retetoff et al. 1975, Nikiforov 2006). The youngest children (<15 
years) are most sensitive to radiation-induced carcinogenesis, and the minimal latent 
period for thyroid cancer development after exposure is as short as 4 years 
(Nikiforov 2006). The vast majority of these cancers are papillary carcinomas. On the 
molecular level, chromosomal rearrangements (such as RET/PTC) are more common 
than point mutations of BRAF and other genes. Radiation exposure only increases 
the risk of developing thyroid cancer; it does not affect the prognosis or the 
aggressiveness of the tumour (Nikiforov 2006). However, treatment with radio-
active iodine has not been shown to increase the incidence of thyroid cancers. 
 
5.3.2 Iodine intake and thyroid cancer 
 
Iodine intake does not seem to influence the incidence of thyroid cancer, but may 
have an effect on the histological type of cancer; in areas of low dietary iodine, 
follicular carcinomas are relatively more common (Feldt-Rasmussen 2001).  
 
5.3.3 Genetic alterations 
 
Activation of receptor tyrosine kinases (RET/PTC, TRK, MET), by rearrangement or 
gene amplification, appears to be specific for the transformation of thyroid follicular 
cells into papillary thyroid carcinomas (Adeniran 2006). These rearrangements 
produce chimeric proteins with tyrosine kinase activities that contribute to the 
development of the malignant phenotype. Approximately 40% of adults with 
sporadic papillary carcinoma have RET gene rearrangement, and about 15% have 
NTRK1 rearrangement (Adeniran 2006). RET/PTC oncoproteins are believed to take 
part in several mechanisms that allow tumour growth and spread, including 
angiogenesis, invasion, metastasis and immune escape. The prevalence of RET/PTC in 
PTCs varies significantly in different studies and geographic regions (Menicali et al. 
2012). Clonal RET/PTC rearrangements are found in 10−20% of adult sporadic papillary 
carcinomas. RET/PTC rearrangements occur with higher incidence in patients with a 
history of radiation exposure (50–80%) (Nikiforov 2011). Several studies have tried to 
associate the presence of a rearranged RET with clinical parameters, yielding 
controversial results. Some studies have indicated an association between RET/PTC and 
a poor prognosis. Conversely, others have found an association with a good prognosis 
(Nikiforov 2011). 
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Follicular carcinomas commonly demonstrate RAS mutations (Nikiforova et al. 2003a, 
Nikiforov 2011). Additional mutations known to occur in poorly differentiated and 
anaplastic carcinomas involve the TP53 and CTNNB1 genes (Nikiforov 2011). 
 
5.3.4 Mutations of BRAF kinase 
 
In recent years, knowledge and understanding of the molecular mechanisms of 
WDTC have increased, and point mutations in the gene coding the protein kinase 
BRAF have been identified as a common genetic event in well-differentiated PTC 
(Cohen at al 2003, Kimura et al. 2003, Nikiforova et al. 2003b). Among the various 
histological subtypes of PTC, BRAF V600E mutation is commonly found in the 
conventional and also tall-cell variants. 
 
BRAF is a member of the RAF kinase family that promotes signaling through the RAS-
RAF-MAPK signal transduction cascade. A simplified schematic illustration of the 
MAPK pathway is given in Figure 2.  
 
 
 
Figure2. RAS-RAF-MAPK signaling cascade with BRAF V600E mutation 
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An activating mutation located on exon 15 of the B isoform of the RAF kinase gene 
results in a valine-to-glutamic acid substitution at amino acid 600 (BRAF V600E). This 
mutation leads to destabilization of the kinase; it promotes a constitutively activated 
state, enhances BRAF kinase activity towards the MAPK kinase and promotes 
tumorigenesis through the MAPK pathway (Davies at al 2002). A higher expression of 
vascular endothelial growth factor in tumours harbouring the BRAF V600E mutation 
has been suggested (Jo et al. 2006), while other studies have reported down-
regulation of VEGF-A and VEGF receptor (Durante et al. 2011). 
 
In recent years, the BRAF mutation has strongly emerged as a molecular marker with 
potential utility in risk stratification for PTC patients (Xing 2007). Since its initial 
description (Cohen et al. 2003, Kimura et al. 2003, Nikiforova et al. 2003b), the BRAF 
V600E mutation has been widely found in PTCs, with a highly variable prevalence 
ranging from 29% to 83%  in different publications (Xing 2005a, Fugazzola et al. 2006), 
and with a mean prevalence of 44% (Xing 2007).  
 
 
5.4 Diagnosis 
 
DTC usually presents itself as a solid, slowly growing non-tender nodule, often 
discovered by chance at a routine clinical examination. Thyroid nodules are relatively 
common, but only approximately 5% are cancers. The cornerstones of diagnostic 
work-up are neck ultrasonography (US) and sonographically guided needle biopsy. 
Fine-needle aspiration biopsy (FNAB) is indicated if the nodule is >1 cm or if there is 
clinical or ultrasonographic suspicion of malignancy (Pacini et al. 2010). 
 
FNAB has an essential role in evaluating nodules detected in US. Papillary carcinomas 
have a distinct cellular appearance and can be diagnosed by a cytological sample 
obtained with fine-needle biopsy. In contrast, the malignancy of follicular neoplasm 
is defined by capsular invasion and cannot be diagnosed by cytological specimens; a 
histological specimen is always warranted.  Pathological diagnostics of thyroid 
neoplasm require considerable expertise. The use of fine-needle aspiration cytology 
increases the diagnostic accuracy of thyroid malignancy cases (Table 1, Cibas and Ali 
2009). Before the routine use of thyroid FNA, the proportion of surgically resected 
thyroid nodules that were malignant was 14%. With current thyroid FNA practices, the 
proportion of resected nodules that are malignant surpasses 50% (Cibas and Ali, 
2009). A uniform system, the Bethesda system with diagnostic categories for 
reporting thyroid cytopathology, was developed in a process hosted by the National 
Cancer Institute (NCI) (Cibas and Ali 2009, Table 2). 
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Table 1. Risk of malignancy in thyroid fine-needle aspiration cytopathology (FNAC ) 
( Bethesda system, Cibas and Ali 2009) 
 
Diagnostic Category Risk of Malignancy (%) 
Non-diagnostic or unsatisfactory 1 – 4 
Benign 0 -3 
Atypia of undetermined significance or 
Follicular lesion of undetermined significance 
5 -15 
Follicular neoplasm or 
Suspicious for a follicular neoplasm 
15 - 30 
Suspicious for Malignancy 60 - 75 
Malignant 97 - 99 
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Table 2. The Bethesda system for reporting thyroid fine-needle aspiration 
cytopathology 
 
I. Non-diagnostic or unsatisfactory 
Cyst fluid only 
Virtually acellular specimen 
Other (obscuring blood, clotting artifact, etc.) 
II. Benign 
Consistent with a benign follicular nodule (includes adenomatoid nodule, colloid nodule, etc.) 
Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context 
Consistent with granulomatous (subacute) thyroiditis 
Other 
III. Atypia of undetermined significance or follicular lesion of undetermined significance 
IV. Follicular neoplasm or suspicious for a follicular neoplasm 
Specify if Hürthle cell (oncocytic) type 
V. Suspicious for malignancy 
Suspicious for papillary carcinoma 
Suspicious for medullary carcinoma 
Suspicious for metastatic carcinoma 
Suspicious for lymphoma 
Other 
VI. Malignant 
Papillary thyroid carcinoma 
Poorly differentiated carcinoma 
Medullary thyroid carcinoma 
Undifferentiated (anaplastic) carcinoma 
Squamous cell carcinoma 
Carcinoma with mixed features (specify) 
Metastatic carcinoma 
Non-Hodgkin lymphoma 
Other 
 
 
CT, MRI, and 123I-scans performed for various indications occasionally reveal thyroid 
nodules, requiring a follow-up ultrasound and FNAB. Similarly, 18F-
fluorodeoxyglucose (FDG) avid nodules incidentally found on PET scans are occurring 
with increasing frequency and may require similar clarification. In addition to data in 
the literature demonstrating accurate detection of thyroid cancer by PET, one study 
proposed that PET may play a role in the management of patients with inconclusive 
cytologic diagnosis of a thyroid nodule (de Geus-Oei 2006). In this study, use of PET 
reduced the number of negative hemithyroidectomies by 66% (de Geus-Oei 2006).  
 
Laboratory tests are generally not useful in diagnostic work-up of DTC. 
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5.5 Prognostic factors and classifications 
 
 
Main prognostic factors include tumour size, patient’s age, extrathyroidal spread and 
histological variant. The presence of vascular invasion, even within the thyroid gland, 
is associated with a more aggressive disease at diagnosis and has a higher incidence 
of tumour recurrence (Nishida et al. 2002). Age is recognized to be the most 
important prognostic factor: age rather than extent of the disease determines the 
stage in the TNM staging system (Cancer Staging Manual, 6th edition, 2002.).  
Multifocality is relatively common, especially in PTC, and has been demonstrated to 
correlate with poor prognosis in some studies (Mazzaferri and Jhiang, 1994). Genetic 
alterations, especially BRAF mutations, have emerged as potentially useful 
prognostic markers. As discussed earlier, many studies have demonstrated 
significant associations between BRAF mutation and high-risk clinicopathological 
characteristics of PTCs (Xing et al. 2005, Xing 2007, Knauf et al. 2009), while some 
researchers have reported that the BRAF mutation has no relationship to poor 
prognosis (Kim et al. 2005b, Liu et al. 2005, Fugazzola et al. 2006, Ito et al. 2009).  
 
Many staging systems have been developed to predict the prognosis of the DTC 
patient. These systems quantify various characteristics of the tumour and the patient 
at the time of diagnosis. Most prognostic classification systems are created and 
validated using cancer-specific death as the outcome.  
 
The most commonly used staging method is the combined American Joint 
Committee on Cancer (AJCC) and International Union against Cancer (UICC) TNM 
classification. The Mayo Clinic has described a prognostic scoring system for papillary 
tumours based on the presence of distant metastasis, patient’s age, completeness of 
resection, tumour invasion and size (MACIS) (Hay et al. 1993). Cady and Rossi (1988) 
described a completely clinical classification based on age of patient, presence of 
distant metastases and the extent and size of the tumour (AMES). Pasieka et al. 
(1992) modified AMES risk-group classification to include DNA ploidy (DAMES). In 
most staging methods, age is a major factor determining prognosis. The TNM and 
MACIS staging methods, primarily predicting the risk for cancer death, are further 
described below.  
 
 
TNM. Tumour, node and metastasis (TNM) for papillary carcinoma of the thyroid are 
classified as follows: 
 
Primary tumour (T)  
 TX: Primary tumour cannot be assessed.  
 T0: No evidence of primary tumour is found.  
 T1: Tumour size is 2 cm or less in the greatest dimension and is limited to the thyroid.  
 T2: Tumour size is greater than 2 cm but less than 4 cm and tumour is limited to the 
thyroid.  
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 T3: Tumour size is greater than 4 cm, and tumour is limited to the thyroid or any 
tumour with minimal extrathyroidal extension (extension to sternothyroid muscle of 
perithyroid soft tissues).  
 T4a: Tumour extends beyond the thyroid capsule and invades any of the following: 
subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  
 T4b: Tumour invades prevertebral fascia or mediastinal vessels or encases the carotid 
artery. 
 
Regional lymph nodes (N)   
 NX: Regional nodes cannot be assessed.  
 N0: No regional node metastasis is found.  
 N1a: Metastasis is found in level VI (pretracheal and paratracheal, including 
prelaryngeal and Delphian) lymph nodes.  
 N1b: Metastasis is found in unilateral, bilateral or contralateral cervical or 
upper/superior mediastinal lymph nodes. 
 
Distant metastasis (M)  
 MX: Distant metastasis cannot be assessed.  
 M0: No distant metastasis is found.  
 M1: Distant metastasis is present. 
 
Table 3. TNM stages of thyroid carcinoma  
 Age under 45 years Age 45 years or older 
Stage I Any T, Any N, M0 T1, N0, M0 
Stage II Any T, Any N, M1 T2, N0, M0 
Stage III  T3, N0, M0, T1, T2, T3, N1a, M0 
Stage IVa  T1, T2, T3, N1b, M0, T4a, N0, N1, M0 
Stage IVb  T4b, any N, M0 
Stage IVc  Any T, any N, M1 
 
 
MACIS: MACIS scoring system for papillary tumours was developed at the Mayo 
Clinic from a cohort of 1779 PTC patients (Hay et al. 1993). The analysis included five 
variables: distant Metastasis, Age, Completeness of surgery, Invasion/Infiltration of 
extra-thyroid tissue and Size of tumour. The MACIS score is calculated as follows: 3.1 
(if age < 40) or 0.08 x age (if  40) + 0.3 x tumour size in cm + 1 (if incompletely 
resected) + 1 (if locally invasive) + 3 (if distant metastases present). A MACIS score 
below 6 indicates a 20-year cause-specific survival of 99% (Hay et al. 1993). 
 
In addition to established prognostic factors (age, tumour histology, tumour 
diameter and metastasis), BRAF V600E mutation has strongly emerged as a 
molecular marker with potential utility in risk stratification for PTC patients (Xing 
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2007). Since its initial description (Cohen et al. 2003, Kimura et al. 2003, Nikiforova et 
al. 2003), BRAF V600E has been widely found in PTCs, with a mean prevalence of 44% 
(Xing 2007). Although some researchers have reported that the BRAF mutation has 
no relationship to poor prognosis (Kim et al. 2005b, Fugazzola et al. 2006, Ito et al. 
2009), many studies have demonstrated significant associations between BRAF 
mutation and high-risk clinicopathological characteristics of PTCs in overall analyses 
of tumours of all sizes (Xing et al. 2005, Xing 2007, Knauf et al. 2009).  Some reports 
have even found a significant association of BRAF mutation in preoperative FNAB 
specimens with poorer clinicopathological outcomes of PTC (Xing et al. 2009). 
Studies on immunohistochemical markers have not shown prognostic capacity 
(Siironen et al. 2005). 
 
Classification into high- and low-risk categories can aid in the determination of 
appropriate primary therapy. The need for prognostic factors to classify patients 
with papillary carcinoma into high- or low-risk categories for mortality and, 
importantly, recurrence is ongoing, and much of current clinical research on papillary 
thyroid carcinoma focuses on this. Headway is being made in the identification of 
genetic markers in tumour cells that indicate prognosis in general, as well as  the 
tendency of the cancer to metastasize. Gene expression patterns have been found 
that can differentiate between benign thyroid tissue and papillary thyroid 
carcinomas, and between papillary and follicular carcinomas (Lubitz at al 2006).  
 
The prognostic factors and classifications proposed for disease recurrence are 
discussed later (section 5.8.1). 
 
 
5.6 Primary treatment 
 
5.6.1 Surgery 
 
Thyroidectomy remains the standard treatment for DTC. The extent of surgery in 
primary therapy is a balance between minimizing complications and improving 
prognosis. Total thyroidectomy is recommended if the primary tumour is 1.0 cm or 
greater, or if extrathyroid extension or metastasis is present (Cooper et al. 2006, 
Pacini et al. 2010). In this surgical procedure, all thyroid tissue is removed so that 
postoperative iodine-131 can be effectively used to eliminate the risk of leaving occult 
disease in the thyroid, and allow serum thyroglobulin levels to be more sensitive in 
detecting recurrent or persistent disease. A near-total thyroidectomy can be 
performed to decrease the risk of damage to the recurrent laryngeal nerve or 
parathyroid glands. Some thyroid tissue is left during the resection and subsequently 
can be ablated with iodine-131. Although the risk of surgical complication is higher 
than that of hemithyroidectomy or near-total thyroidectomy, most experts agree 
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that the risk of recurrent disease is lower and the survival rate is higher after total 
thyroidectomy (Hay et al. 2002, Bilimoria et al. 2007). 
 
It has been much debated whether hemithyroidectomy is the most appropriate 
treatment for small (<1 cm) low-risk papillary carcinoma that is macroscopically 
localized in one lobe or for patients with occult papillary thyroid cancers (Haigh et al. 
2005, Bilimoria et al. 2007, Ogilvie et al. 2010). Less extensive surgery may be justified 
in case of a small (<1 cm) DTC diagnosed after surgery for a benign condition (Pacini 
et al. 2010). According to the revised American Thyroid Association guidelines, for 
patients with thyroid cancer >1 cm, the initial surgical procedure should be a near-
total or total thyroidectomy unless there are contraindications to this surgery 
(Cooper et al. 2009). Thyroid lobectomy alone may be sufficient treatment for small 
(<1 cm), low-risk, unifocal, intrathyroidal papillary carcinomas in the absence of prior 
head and neck irradiation or radiologically or clinically involved cervical nodal 
metastases (Cooper et al. 2009). Lobectomy may also sometimes be a good choice 
for patients who may not be compliant with thyroid hormone replacement 
postoperatively. However, a significant increase in recurrences locally or in the 
contralateral lobe has been observed in patients who have had only a lobectomy 
(Bilimoria et al. 2007).  
 
An even more conservative approach of non-surgical observation has been 
suggested for the most benign, incidentally detected papillary thyroid 
microcarcinomas (Sugitani et al. 2010). This includes follow-up with neck US and 
lobectomy and a more radical surgical approach in case of observed growth.  
 
Cervical lymph node involvement is common in papillary thyroid carcinoma, with 
positive adenopathy or micrometastatic lymphatic deposits in approximately 35% (25 
− 60 %) of cases. However, long-term survival has been the norm even in the setting 
of extensive neck disease (Mazzaferri and Jhiang 1994).  
 
Prophylactic central neck dissection (PCND) is defined as the removal of seemingly 
normal lymph nodes during the initial operation. The rationale for PCND rather than a 
selective approach is that ability with preoperative US or with intra-operative 
assessment to adequately evaluate the central neck compartment has been 
questioned. A comprehensive review and meta-analysis on the subject are pending. 
 
Elective neck dissection rates vary in different centres. Performing elective central 
node dissection in the setting of larger (>1 cm) and multifocal papillary thyroid 
carcinomas may have advantages. These have been suggested to be the following 
(Guerrero and Clark 2011):  
 
 Provides more accurate tumour staging 
 Decreases rate of local recurrence 
 Reduces likelihood of a more challenging reoperation carrying a higher risk of 
complications 
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 Reduces local tumour load, which may increase radio-active iodine uptake in distant 
metastatic foci, if present 
 Renders more patients athyroglobulinemic, again by reducing local tumour load, 
allowing better surveillance. 
 
Treatment with total or near-total thyroidectomy results in a higher surgical 
complication rate, while more conservative measures result in a higher rate of 
postoperative cancer recurrence. The most common significant complications of 
thyroid surgery are permanent recurrent laryngeal nerve palsy and permanent 
hypoparathyroidism. In experienced centers, they occur in 1−2% of the procedures 
(Pacini et al. 2010).  
 
5.6.2 Postoperative radio-iodine ablation 
 
Thyroid tissue has the ability to accumulate iodine from the bloodstream via an 
active, energy-dependent transport process, the sodium/iodide symporter (NIS). 
Accumulation is 20- to 40−fold in the thyroid gland, beginning rapidly after iodine 
ingestion. The radiation dose delivered to the thyroid gland is 1000- to 10000–fold 
that of surrounding tissues. This is the basis for using radio-active iodine (RAI) in the 
treatment of DTC.  RAI is produced in nuclear reactors by neutron irradiation of 
tellurium or as a product during fissioning of uranium. At ingestion and uptake to 
thyroid tissue, physically unstable radio-active 131I reverts to a stable state by ejecting 
beta particles. This beta radiation has a capacity to penetrate only up to 2 mm into 
the surrounding tissue. Beta particles account for about 90% of the radiation 
delivered by RAI, the rest is gamma radiation which leaves the patient mainly via the 
skin surface. Beta radiation is responsible for the treatment effects of radio-iodine, 
whereas gamma radiation allows for scanning the effects. The outcome of radio-
iodine therapy is dependent on the uptake and retention of iodine by thyroid tissue. 
131I ablation allows the eradication of thyroid remnants and improves the diagnostic 
value of serum TG determination both on and off L-T4 treatment for surveillance 
(Toubeau et al. 2004, Kim et al. 2005a). 
 
Despite the widespread use of RAI, data on effectiveness are controversial. Cohort 
studies have shown improved survival and reduced tumour recurrence when iodine-
avid, advanced-stage, well-differentiated thyroid cancer is treated with radio-active 
iodine (DeGroot et al. 1994, Mazzaferri 1997). RAI has also been shown to reduce 
disease-specific mortality in high risk DTC in several studies (Mazzaferri and Kloos 
2001, Sacks 2010).  For low-risk DTC, the data are less clear.  
 
A recent meta-analysis concluded that substantial evidence suggests that RAI is not 
associated with improved survival in low-risk or low-stage DTC (Sacks et al. 2010). 
This review of 79 published studies on RRA concluded that the majority of studies did 
not find a statistically significant improvement in mortality or disease-specific survival 
in low-risk patients treated with RAI (Sacks et al. 2010). Evidence regarding 
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recurrences was mixed, with half of the studies showing a significant relationship 
and half showing no relationship (Sacks et al. 2010). In another large retrospective 
analysis of 1298 low-risk DTC patients with a median follow-up of 10.3 years RRA, was 
not associated with improved overall survival or disease-free survival (Schvartz et al. 
2012). 
 
According to the American Thyroid Association recommendations, radio-iodine 
remnant ablation (RRA) after total thyroidectomy for DTC is indicated in patients 
with moderate to high risk of recurrent or persistent disease, based on age, tumour 
size, extrathyroidal extension, lymph node status and histology (Cooper et al. 2009). 
In contrast, for low-risk patients the use of RAI remains controversial and the benefit 
for survival or recurrence-free survival is more uncertain (Sawka et al. 2004, Sawka et 
al. 2008) and thus a more selective use is encouraged (Cooper et al. 2009).  RRA is 
not indicated in patients with very low-risk tumours (Table 4, Pacini et al. 2010). The 
recommendations and the evidence are summarized in Table 5. 
 
 
Table 4. Risk stratification for DTC patients according to the European Consensus 
Report (Pacini et al. 2010) 
 
Very low-risk Low-risk High risk 
Intrathyroidal tumour  
T1 ≤ 1 cm 
Intrathyroidal tumour  
T1 > 1 cm and T2 
Intrathyroidal tumour  
T3 
No aggressive histology Aggressive histology Microscopic or macroscopic 
invasion (T3-T4) 
No local or distant 
metastasis 
No local or distant 
metastasis 
Locoregional metastasis 
Distant metastasis 
Complete surgery Less than total 
thyroidectomy 
Incomplete resection 
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Table 5. Major factors impacting decision-making in radio-iodine remnant ablation 
(adapted and modified from Cooper et al. 2009)  
 
  Expected benefit according to 
current evidence 
 
Factor Description Decreased 
risk of death 
Decreased risk of 
recurrence 
RAI ablation usually  
recommended 
T1 1 cm or less, 
intrathyroidal or 
microscopic 
multifocal 
 
No 
 
No 
 
No 
 1–2 cm, 
intrathyroidal 
No Conflicting data Selective use 
T2 >2–4 cm, 
intrathyroidal 
No Conflicting data Selective use 
T3 >4 cm No   
 <45 years old No Conflicting data Yes 
 ≥45 years old Yes Yes Yes 
 Any size, any age, 
minimal 
extrathyroidal 
extension 
 
No 
 
Inadequate data 
 
Selective use 
T4 Any size with 
gross 
extrathyroidal 
extension 
 
Yes 
 
Yes 
 
Yes 
N1 <45 years old No Conflicting data Selective use 
 ≥45 years old Conflicting 
data 
Conflicting data Selective use 
M1 Distant metastasis 
present 
Yes Yes Yes 
 
 
The optimal administered activity of RAI to ablate the thyroid remnant remains 
controversial. The administered activities have varied widely between centres and 
have been determined either empirically or with dosimeter tools.  
 
Prospective randomized studies comparing different activities of RAI (1.1 GBq vs. 3.7 
GBq, e.g. 30 vs. 100 mCi) have been published in recent years (Mäenpää et al. 2006, 
Mallick et al. 2012, Schlumberger et al. 2012). In these studies, successful ablation 
rates were comparable between the groups, with better tolerability and shorter 
need for radiation protection in the 1.1 GBq group (Mäenpää et al. 2006). Two studies 
additionally compared preparation for ablation with rhTSH with thyroid hormone 
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withdrawal and found the ablation rate equivalent between the two methods 
(Mallick et al. 2012, Schlumberger et al. 2012).  
 
The side-effects of RAI therapy may occur in many areas and organ systems. Acute 
and mostly transient adverse effects have included hypothyroidism-induced 
decreased quality of life before radio-active iodine treatment and local effects upon 
administration. Recent studies have demonstrated that use of rhTSH is highly 
effective and safe and that the rate of successful ablation is similar to that obtained 
with L-T4 withdrawal (Pacini et al. 2006a, Pilli et al. 2007). 131I radio-active iodine is 
also associated with long-term dose-dependent adverse systemic and local effects, 
such as those on the salivary glands and nasolacrimal ducts, resulting in xerostomia 
and dental problems. In a series of 160 DTC patients comparing low vs. high activity 
of 131I, Mäenpää et al. found that all acute adverse effects were mild (grade 1 or 2) 
except for nausea, which was severe in four patients(6%)  in the low activity and in 
seven patients (10%) in the high activity group. All adverse effects also decreased in 
the three-month follow-up.  
 
Radio-active iodine may also have serious long-term health risks. NIS gene is 
expressed in tissues besides the thyroid gland, which appears to result in an 
increased risk of second primary malignancies after radio-iodine treatment, as shown 
in recent studies (Rubino et al. 2003, Sandeep et al. 2006). In a European pooled 
cohort, a relationship was found between 131I administration and occurrence of bone 
and soft tissue, colorectal and salivary gland cancers (Rubino et al. 2003). The 
association was seen even in low-risk patients, the greatest risk being for leukaemia 
(2.5-fold increase). Results are controversial regarding breast cancer, stomach cancer 
or other solid tumours. Some authors have demonstrated that patients with DTC 
have an overall increased standardized incidence rate for second primary tumours, 
but not for second primary tumours following 131I therapy (Verkooijen et al. 2006). 
These findings suggest a common mechanism for these cancers, aetiologic and/or 
genetic, instead of a causal relationship with RAI. 
 
In a pooled cohort analysis, an increasing risk for both solid tumours and leukaemias 
was seen with increasing cumulative dose of 131I; an excess of 4% per GBq was 
calculated (Rubino et al. 2003). Use of external radiotherapy did not influence the 
relationship; i.e. the excessive risk remained the same (Rubino et al. 2003).  
 
Infertility and gonadal failure have also been studied in correlation with 131I therapy. 
After RRA, transient amenorrhea in women and azoospermia in men have been 
observed. With multiple treatments, the effects in male reproductive organs may be 
permanent (Pacini et al. 1995).  
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5.6.3 Thyroxine therapy 
 
After thyroidectomy, the need for thyroid hormone substitution is permanent. 
Thyroid-stimulating hormone (TSH) suppression therapy by administration of 
thyroxine has been used for many years. The correlation between TSH suppression 
and disease outcome remains somewhat controversial. In postoperative patients 
with low-risk papillary thyroid carcinoma, the recurrence rate and survival rate 
among TSH-suppressed and TSH-nonsuppressed individuals seem to be similar 
(Sugitani and Fujimoto 2010). Nevertheless, some studies have indicated that non-
suppressed TSH is related to an increased risk of DTC recurrence independent of 
tumour type and TNM stage (Böhm et al. 1999). In advanced disease, however, TSH 
suppression has been shown to correlate with better disease outcome; in a study of 
157 patients, DTC-specific survival was significantly better in patients with a median 
TSH level ≤0.1 mU/l (median survival 15.8 years) than in those with a non-suppressed 
TSH level (median survival 7.1 years) (Diessl et al. 2012). 
 
Suppressive thyroxine therapy has also been correlated with a number of side-
effects, though the evidence is inconsistent. A decreased bone mineral density, 
diastolic heart failure, cardiac arrhythmias, primarily atrial fibrillation and increased 
risk of thrombosis are among the possible side-effects (Toivonen et al. 1998, Horne 
et al. 2004, Heijckman et al. 2005, Smit et al. 2005).  Most centres do not administer 
thyroid hormone to suppress TSH in patients with low-risk papillary thyroid 
carcinoma and recent guidelines also advise total suppression of TSH only in the high-
risk patient group (Cooper et al. 2006, Cooper at al 2009, Pacini et al. 2006, Pacini et 
al. 2010). 
 
 
 
5.7 Follow-up 
 
The European guidelines for the management and follow-up of low-risk DTC patients 
were updated and published recently (Schlumberger et al. 2004, Pacini et al. 2006, 
Pacini et al. 2010). Their cornerstones are total thyroidectomy, 131I ablation, post-
therapy whole-body scan (WBS), and neck ultrasonography (US) and (rhTSH-
stimulated) TG measurements without diagnostic WBS (DxWBS) 6-12 months after 
primary treatment (Figure 3). If TG is undetectable and neck US normal, indicating 
disease-free status, the patient will be followed only with TG measurement on L-T4 
and neck US (Schlumberger 2005, Pacini et al. 2006, Pacini et al. 2010). The consensus 
report by American and European authors contains basically the same elements, but 
neck US is recommended only for those with rhTSH-stimulated TG above 2 μg/L 
(Pacini et al. 2002, Pacini et al. 2006, Cooper et al. 2009).  
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Figure 3. Proposed flow chart for the follow-up after initial treatment  
(adapted and modified from Pacini et al. 2006)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The European Society of Medical Oncology (ESMO) guidelines for DTC recommend 
basal and stimulated TG measurement 6-12 months after initial therapy together with 
neck US and with or without WBS to confirm remission (Pacini et al. 2010). If the 
patient is disease-free at this point, he/she is categorized as low-risk and followed up 
with TG measurements on thyroxin and neck US yearly (Pacini et al. 2010).  
  
5.7.1 Serum thyroglobulin measurements 
 
Thyroglobulin (TG) is produced only by thyroid follicular cells and serves as the 
prohormone for thyroid hormone production. Serum TG levels reflect three factors: 
the mass of thyroid tissue, the level of TSH stimulation and any damage or 
inflammation of thyroid tissue. Following total thyroid ablation, TG should be 
undetectable in serum and any detectable level then indicates the persistence or 
Increased 
Detectable, 
decreasing:  
re-test in 1 year Undetectable 
Yearly evaluation  
TG –on LT4, neck US 
Treatment with RAI, 
RxWBS and /or surgery 
TSH-stimulated TG yearly 
TTE + RRA 
RxWBS 
Detectable TG and/or 
abnormal US 
 
Low detectable TG 
Normal US 
Undetectable TG 
Normal US 
Check for TSH, T4 –on LT4  
at 3 months 
TG + neck US, using rhTSH  
at 6-12 months 
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recurrence of neoplastic disease. This is the basis for the use of TG as a postoperative 
tumour marker in the follow-up of thyroid cancer patients. After surgery and RRA, 
serum TG measurement is sensitive and specific; the mainstay for the follow-up of 
DTC patients (Schlumberger and Baudin 1998, Robbins et al. 2002, Faterni and 
LoPresti 2003, Kloos and Mazzaferri 2005, Mazzaferri et al. 2003). The significance of 
thyroglobulin levels may be lost in patients with circulating thyroglobulin antibodies. 
 
Ongoing debate exists as to whether after primary evaluation of response, serum TG 
measurements should be performed on or off L-T4 or after the stimulation by rhTSH 
or thyroxine withdrawal (Rosario et al. 2005, Pacini et al. 2010). Recently, a large 
prospective study evaluating the prospective capacity of TG demonstrated that 
stimulated TG determination presented only a slightly higher sensitivity than TG 
determination on L-T4 (Brassard et al. 2011). The ESMO clinical guideline suggests no 
stimulated TG measurements for the very low-risk group and every 12 months for 
intermediate-, and high-risk groups (Pacini et al. 2010). 
 
Thyroglobulin is today being measured by sensitive immunoassays. The availability of 
these second-generation assays has resulted in revision of the guidelines (Cooper et 
al. 2009) with regard to TSH stimulation. The need for stimulation may be reduced in 
low-risk patients with initial negative TG after primary therapy (Cooper et al. 2009). 
At the same time, with very sensitive assays, the risk for minimally measurable 
concentrations resulting in unnecessary procedures (radiology or radioisotope) is 
recognized.  
 
5.7.2 Diagnostic whole-body scan in follow-up 
 
In the past, routine DxWBS together with serum TG measurements was considered 
the main tool for detecting persistent or recurrent disease (Schlumberger 1998, 
Mazzaferri and Kloos 2002). In the past ten years, the sensitivity of DxWBS for this 
purpose has been questioned and demonstrated to be low (Cailleux et al. 2000, 
Pacini et al. 2002, Mazzaferri and Kloos 2002).  Many studies have shown  that 
DxWBS does not add much to the information gained from serum TG measurements 
on existing recurrence, especially when  stimulation by rhTSH is used (Pacini et al. 
2002, Mazzaferri and Kloos 2002, Baudin et al. 2003). Today, DxWBS is increasingly 
aimed only at ascertaining the completeness of primary RRA. For TG−positive and 
WBS−negative patients, FDG-PET is increasingly utilized (Salvatore et al. 2008, Ma et 
al. 2010).  
 
 
5.7.3 Neck ultrasonography 
 
Traditional techniques, DxWBS foremost, for surveillance of DTC have in the past ten 
years been found to be less sensitive than ultrasonography (US) in the detection of 
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neck recurrences. In the low-risk patient cohort, neck recurrences are most common. 
Neck US detects recurrences in patients with undetectable serum TG levels and 
negative WBS; neck US in combination with TG has been demonstrated to be an 
effective and sensitive surveillance method to detect recurrences (Frasoldati et al. 
2002, Pacini et al. 2003, Torlontano et al. 2004). Most guidelines now agree that neck 
US should be performed as the first-line investigation in the follow-up of all DTC 
patients (Schlumberger et al. 2004, Pacini et al. 2006). Neck US should always be 
performed by experienced radiologists or clinicians. 
 
Fine-needle aspiration biopsy (FNAB) has an essential role in evaluating nodules 
detected in US. Before the routine use of thyroid FNA, the proportion of surgically 
resected thyroid nodules that were malignant was 14%. With current thyroid FNA 
practices, the proportion of resected nodules that are malignant surpasses 50% 
(Cibas and Ali 2009).  
 
 
 
5.7.4 Recombinant human thyrotropin 
 
A relatively new discovery for postoperative DTC patients is the administration of 
recombinant form of human thyrotropin or TSH (rhTSH) without causing symptoms 
of hypothyroidism. rhTSH is a heterodimeric glycoprotein produced by recombinant 
DNA technology; it has comparable biochemical properties to pituitary TSH.  
 
Today, rhTSH has been shown to effectively replace thyroid hormone withdrawal in 
thyroid remnant ablation and in the follow-up of thyroid cancer patients (Haugen et 
al. 1999, Robbins and Robbins 2003, Pacini et al. 2006a, Duntas et al. 2008). Patients 
may now be given rhTSH to prepare them for whole-body scanning or ablation 
(Figure 4) and to entirely avoid the 4− to 6−week ordeal of levothyroxine withdrawal, 
hypothyroidism-linked health problems and impaired quality of life (Schlumberger et 
al. 2002, Luster et al. 2005a). Pharmacoeconomic considerations are also important. 
The use of rhTSH carries potential economic savings from preserving the ability to 
work, which in many cases offsets the direct costs (Luster et al. 2005b). 
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Figure 4. Schematic example of rhTSH administration 
 
Ablation schedule 
Day 1 Day 2 Day 3 
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injection 
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Radio-iodine 
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First rhTSH 
injection 
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Radio-iodine 
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Measurement 
of serum TG +/- 
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5.8 Outcome and recurrences 
 
In general, the prognosis for differentiated carcinoma of the thyroid is excellent. 
Long-term survival rates of approximately 90% are usually given. However, up to 
30−40% of patients develop tumour recurrence (Mazzaferri and Jhiang 1994). Two-
thirds of recurrences occur within the first decade after therapy. Tumours recur 
outside the neck in about 21% of cases. The most common site for distant metastasis 
is the lung. Mortality rates are lower when recurrences are detected early based on 
radio-iodine scans rather than clinical signs.  
 
In a recently published large population-based study of over 50 000 patients, the 
recurrence rates were 5.7% at 5 years and 9.4% at 10 years (Bilimoria et al. 2007). Both 
recurrence and survival were associated with tumour size; 10-year survival rates 
declined with increasing tumour size (Bilimoria et al. 2007). 
 
5.8.1 Prognostic factors and risk group classification for disease recurrence 
 
According to the American Thyroid Association, to assess the risk of recurrence, a 
three-level stratification to low-risk, intermediate-risk and high-risk patients can be 
used (Cooper et al. 2009): 
 
Low-risk patients have the following characteristics:  
 no local or distant metastases  
 all macroscopic tumour has been resected 
 no tumour invasion of locoregional tissues or structures  
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 the tumour does not have aggressive histology (e.g., tall cell, insular, columnar cell 
carcinoma) or vascular invasion  
 and, if 131I is given, there is no 131I uptake outside the thyroid bed on the first post-
treatment whole-body RAI scan (RxWBS) 
 
Intermediate-risk patients have any of the following:  
 microscopic invasion of tumour into the perithyroidal soft tissues at initial surgery 
 cervical lymph node metastases or 131I uptake outside the thyroid bed on the RxWBS 
done after thyroid remnant ablation  
 a tumour with aggressive histology or vascular invasion   
 
High-risk patients have the following characteristics: 
 macroscopic tumour invasion  
 incomplete tumour resection  
 distant metastases 
 and possibly thyroglobulinemia out of proportion to what is seen on the post-
treatment scan  
 
The European Society of Medical Oncology (ESMO) guideline for DTC recommends 
stratification to these three groups. The postoperative clinicopathological staging 
system should be used, in conjunction with the AJCC staging system to improve 
prediction of risk for recurrence and to dictate the most appropriate therapy (Pacini 
et al. 2010). 
 
Unlike staging according to the TNM staging system and others, depending on the 
clinical course of the disease and response to therapy, the risk of recurrence may 
change over time. Appropriate management requires an ongoing reassessment of 
the risk of recurrence and the risk of disease-specific mortality as new data are 
obtained during follow-up (Cooper et al. 2009).  
 
Evidence has accumulated to support a more ongoing risk stratification, which takes 
into account the response to initial therapy. Successful ablation, measured by 
negative post-treatment scan and undetectable serum TG, has been shown to 
correlate with better outcome (Verburg et al. 2005). Undetectable serum TG after 
primary therapy by itself has also been reported to correlate with better outcome 
(Toubeau et al. 2004, Kloos and Mazzaferri 2005, Kim et al. 2005a, Brassad et al. 
2011).  
 
On this basis, patients can be classified as having an excellent, acceptable or 
incomplete response to therapy (Tuttle 2008). Patients with an excellent response 
(undetectable basal and stimulated TG, negative TG antibodies and negative neck 
US) should have a very low-risk of recurrence and their long-term follow-up is based 
on yearly physical examination and suppressed TG value. Patients with an acceptable 
response (undetectable basal TG, stimulated TG <10 ng/ml, trend of declining TG,  
TG-Ab absent or declining, substantially negative neck US) require a closer follow-up, 
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reserving additional treatment in the case of any evidence of disease progression. 
Patients with an incomplete response (detectable basal and stimulated TG, trend of 
TG stable or rising, structural disease present, persistent or recurrent RAI-avid 
disease present) require continued intensive follow-up with neck ultrasound, cross-
sectional imaging, RAI imaging and FDG-PET imaging (Pacini et al. 2010). 
 
5.9 Health-related quality of life (HRQoL) 
 
Studies on health-related quality of life (HRQoL) after primary treatment of DTC 
patients are limited in number. Most studies have demonstrated some impairment of 
HRQoL (Botella-Carretero et al. 2003, Crevenna et al. 2003, Tagay et al. 2005, 
Hoftijzer et al. 2008). One study assessed HRQoL in 153 cured DTC patients with the 
validated health-related questionnaires SF-36, MFI-20, HADS and SDQ and compared 
the results with those of 113 healthy controls, selected by the patients themselves, 
and 336 age- and gender-matched controls from other local studies. Duration of cure 
varied considerably (0·3–41·8 years). Quality of life was impaired in DTC patients 
relative to the two control groups in 11 and 13 of 16 subscales, respectively (Hoftijzer 
et al. 2008). These studies include reports on the short-term effects of 
hypothyroidism or subclinical hyperthyroidism on quality of life in DTC patients 
(Botella-Carretero et al. 2003, Tagay et al. 2005, Tan et al. 2007).  
 
The long-term effect of thyroid cancer on HRQoL has been the subject of only a few 
surveys. Schultz and colleagues have described the health profiles of 518 thyroid 
cancer survivors, as part of a large cancer survival survey (Schultz et al. 2003).  The 
survey, which was designed for adult survivors of any cancer, consisted of questions 
concerning health effects of cancer on neurological, cardiovascular, musculoskeletal, 
gastrointestinal, genitourinary, pulmonary, integumentary, psychological, endocrine 
and sociocultural functions. In this study, thyroid cancer survivors reported more 
memory loss and psychological problems than survivors of other cancers, and more 
migraine headaches than other cancer survivors or the general population (Schultz et 
al. 2003). In a study of 150 DTC patients with a median time of 5.5 years from 
diagnosis, using the SF-36 survey, an impairment in HRQoL was seen during the first 
year after diagnosis. Thereafter, quality of life improved correlating with the time since 
initial diagnosis (Crevenna et al. 2003). 
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6 AIMS OF THE STUDY 
 
 
 
 
 
The prevalence of particularly low-risk DTC is increasing, and the number of patients 
who need long-term follow-up is considerable. General guidelines are most suitable 
for low-risk patients; for high-risk patients, a tailored approach is always warranted. 
Identifying novel factors prognostic of disease recurrence is an important goal of 
current research activity. At HUCH, a uniform treatment and surveillance scheme of 
low-risk DTC patients has been used for more than 20 years, providing an adequate 
perspective on the follow-up of low-risk patients. Specific aims of this study were as 
follows: 
 
 
 To analyse the long-term outcome of patients treated for TNM stage I or II low-risk 
differentiated thyroid carcinoma, and in remission, at HUCH between 1983 and 1997. 
  
 To find factors prognostic of recurrence of patients with low-risk differentiated 
thyroid carcinoma. 
 
 To evaluate the prognostic capability of BRAF V600E mutation for recurrence in a 
patient population with low-risk for cancer-specific death. 
 
 To compare HRQoL of patients who have undergone treatment for low-risk DTC with 
the age- and gender-matched general population. 
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7  MATERIALS AND METHODS 
 
 
The study was carried out at Helsinki University Central Hospital (HUCH) and the 
University of Helsinki between 2001 and 2011. HUCH provides specialist health care 
for a district with approximately 1 425 000 inhabitants (the Uusimaa region). Patients 
with DTC are treated and followed up at the Division of Endocrinology, Department 
of Medicine and Department of Oncology. Patients with persistent disease are 
followed up by oncologists, whereas those considered disease-free are referred to 
the Division of Endocrinology for five years. Thereafter, the follow-up takes place at 
the local hospital for additional five years.   
 
All patient data were collected by reviewing the original patient records. Data on 
patients’ current addresses were provided by the Finnish Population Registry Centre. 
Causes of death were provided by Statistics Finland.   
 
 
7.1 Study approval  
 
The study protocol was reviewed and approved by the Ethics Committee of HUCH. 
 
 
7.2 Subjects and methods 
 
For this study, the clinical records of 710 patients (571 female, 139 male) diagnosed 
with and treated for papillary or follicular thyroid carcinoma over a 15-year period 
from 1st January  1983 to 31st December 1997 in the HUCH district were reviewed. The 
study cohort comprises those DTC patients belonging to TNM stage I or II who were 
considered to be disease-free and in complete remission after initial treatment 
(n=495, 70% of all). 
 
The major data collection time-points were in 2002 and 2007. These time-points were 
chosen so that all patients would have a follow-up period of five years or more and 
ten years or more, respectively.  
 
Demographic data included patients’ age at diagnosis, sex, date of operation and 
data on causes of any death, provided by the Finnish Population Registry. Data on 
tumour size, histological diagnosis and invasiveness, local and distant metastasis, 
postoperative and post-ablative thyroglobulin levels as well as data on primary 
treatment, including mode of operation, radio-active remnant ablation and activity of 
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RAI, external radiation and judgment of completeness of surgery, were collected. 
Records of all follow-up visits (n=2559) were reviewed, and data on all tests and 
examinations utilized were recorded (including laboratory, radiological and other 
parameters). 
 
7.2.1 Subjects in Studies I and II 
 
The study cohort in Studies I and II consisted of 495 (83.8% female and 16.2% male) 
patients with TNM stage I or II differentiated thyroid carcinoma and considered to be 
disease-free after initial therapy.  Mean age at diagnosis was 40.6 years. 
 
For BRAF mutation analysis (Study III), all patients with papillary tumours and disease 
recurrence (n=46) were considered. Age- and gender-matched controls were chosen.   
 
For Study IV, 417 patients (84% of study cohort) were invited to participate in the 
HRQoL study. Patients with occult carcinomas or patients with lobectomy as initial 
treatment were excluded. Altogether 341 patients replied, resulting in a response 
rate of 81.1%. 
 
7.2.2 Tumour staging 
 
The tumours were staged according to the AJCC, 6th edition. The papillary tumours 
were additionally staged according to the MACIS prognostic scoring system. 
 
7.2.3 Disease recurrences 
 
A disease recurrence was defined as new evidence of disease after a disease-free 
period of 12 months or more. It included all sites of disease reported and confirmed 
by either imaging or surgery. A new uptake on DxWBS, a newly measurable TG, a 
clinical finding with histological conformation or a lesion in neck US with positive 
FNAB or histological finding were considered.  A disease-free period of 12 months or 
more was necessary before the diagnosis of recurrence; otherwise, it was classified 
as persistent disease and excluded. Time to disease recurrence was calculated from 
the date of initial surgery. For TG, the detection limit of the method used at each 
time-point was used as cut-off value distinguishing between measurable and non-
measurable findings. 
 
A questionnaire was sent in 2002 and again in 2007 to all patients whose follow-up 
had been referred from HUCH to another hospital. The questionnaire clarified 
possible suspicion of recurrence and possible side-effects of primary treatment 
during follow-up. A separate standardized questionnaire, the 15D™ (Sintonen 2001), 
evaluating patients’ HRQoL was also sent to all patients in 2002. 
 41 
 
 
7.2.4 Thyroglobulin measurements 
 
Until 1989, serum TG was measured by an RIA kit (Medix Laboratories Ltd., 
Kauniainen, Finland) with a detection limit of 3 mg/l, and after that by an 
immunometric sandwich assay using two MABs (AutoDelfia, Perkin Elmer, Wallac, 
Turku, Finland) with a detection limit of 1 mg/l. Prevalence of anti-TG antibodies was 
evaluated using the recovery method according to the manufacturer’s instructions 
(Delfia TG (hTG), Perkin Elmer). A recovery of >80% was considered normal and 
excluded the presence of anti-TG antibodies.  
 
7.2.5 BRAF mutation (Study III) 
 
To evaluate the prognostic quality of BRAF mutation, original tumour tissue samples 
of PTC patients with a disease recurrence after a median follow-up of 16 years (n=46) 
were located. Twenty-six original tumour tissue samples were retrievable; these 
were re-evaluated by an experienced thyroid pathologist.  Representative tumour 
slides with a minimum of 30% of tumourous tissue were chosen for further analysis. 
Age- and gender-matched controls with retrievable tissue samples and no disease 
recurrence were selected. 
 
Paraffin-embedded tumour tissues were processed for DNA extraction. For the BRAF 
mutation V600E test, DNA was extracted by using the Quiagen mini extraction kit.  
For mutation analyses, ARMS (allelic-specific PCR) with Scorpions real-time PCR 
technology was applied according to the instructions given by the supplier (B-RAF 
Mutation Test Kit; BR-01, Qiagen DxS). 
 
7.2.6 Measurement of health-related quality of life (Study IV) 
 
HRQoL was measured by the 15D tool (Sintonen 2001). This is a generic, 
comprehensive, 15-dimensional, standardized, self-administered measure of HRQoL 
that can be used both as a profile and single index instrument. The 15D questionnaire 
consists of 15 dimensions: mobility, vision, hearing, breathing, sleeping, eating, 
speech, elimination, usual activities, mental function, discomfort and symptoms, 
depression, distress, vitality and sexual activity. Each dimension is divided into five 
ordinal levels, to assess the extent of the attribute. The subject chooses the level 
best describing his or her current health status for each dimension. The evaluation 
system of the 15D is based on an application of the multi-attribute utility theory. A set 
of utility or preference weights, elicited from the general public through a 3-stage 
evaluation procedure, is used to generate the within-dimension level values and the 
overall utility score, i.e., the 15D score (single index number) over all the dimensions 
on a 0-1 scale.  The maximum score is 1 (no problems on any dimension), and 
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minimum score 0 (equal to being dead). The minimal clinically important difference 
of the 15D score is 0.03. 
 
The 15D questionnaire was posted to the patients. The HRQoL data obtained were 
compared with that of a large, representative sample of the general Finnish 
population. The 15D data for the general population came from the National Health 
2000 Health Examination survey representing the Finnish population aged 30 years 
and over (Aromaa and Koskinen 2004). For the present analysis, individuals who 
were in the age range of the patients (n=6001) served as a comparative population. 
This sample was weighted to reflect the age and gender distribution of the patients.   
 
 
7.3 Statistical analysis 
 
The statistical analyses were carried out using a NCSS 2000 software package (NCSS 
Statistical Software, Kaysville, UT, Study I) or S+ Software (Studies II, III and IV). A p-
value less than 0.05 was regarded as statistically significant. All tests were performed 
as two-sided tests. The following tests were used: 
 
Study I: For comparisons between patients with or without recurrence, Fisher’s exact 
test for two proportions was used. The assumptions for Student’s t-test were not 
fulfilled for the variables of age, size and MACIS, which were evaluated using Mann-
Whitney U-test or Wilcoxon rank-sum test for difference in medians. Independent 
predictors for recurrence were studied using forward stepwise regression analysis.  
Study II: The relationships between recurrence and explanatory factors were first 
examined using simple logistic regression. A multiple logistic regression model 
including all significant factors in the first analysis was created (hazard ratio with 95% 
confidence intervals). A p-value of less than 0.05 was considered statistically 
significant.  
Study III: The relationships between recurrence and explanatory factors were 
examined using simple logistic regression for each factor separately. Comparison of 
patient and tumour characteristics according to BRAF V600E mutation status was 
performed with simple logistic regression, Fisher’s exact test, Wilcoxon rank-sum 
test or two-sample t-test. In these analyses, BRAF V600E mutation status was 
handled as a factor. A p-value of less than 0.05 was considered statistically 
significant.  
Study IV: Differences in the means of continuous variables were tested with 
independent samples t-test and in categorical variables with Pearson Chi-square test. 
Differences between the mean 15D scores and dimension level values between 
participants and the control group were tested with independent samples t-test. The 
variance in the 15D scores among the survey participants was explained by a Tobit 
regression model. 
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8 RESULTS 
 
8.1 Patient and tumour characteristics  
 
The study cohort of 495 low-risk DTC patients in studies I, II and IV consisted of 415 
(83.8 %) females and 80 (16.2 %) males. Mean age at diagnosis was 40.6 years. A 
majority (93.1%) of the tumours were of papillary histology, 6.3% were follicular and 
0.6% other (Hürthle-cell and mucoepidermoid variants). Median tumour size was 1.8 
cm (range 0.3 to 6.0 cm) for all tumours and 1.6 cm (0.3 to 6.0 cm) for papillary and 
3.0 cm (0.6 to 6.0 cm) for follicular tumours. The follicular tumours were significantly 
larger in diameter than the papillary tumours (P<0.0001). In 11 cases (2.2%), tumour 
size was not recorded in either surgical or histological reports. 
 
 
Table 6. Tumour characteristics expressed as median (range) or number 
(percentage) 
 All 
n = 495 
Papillary 
 n = 461          
Follicular  
n = 31            
Other 
 n = 3 
 
Size (cm) 
 
 
1.8 (0.3 – 6.0) 
 
1.6 (0.3 – 6.0) 
 
3.0 (0.6 –6.0) 
 
1.5 (1.5 – 2.0) 
 
Macroscopic 
infiltration 
 
37 (7.4%) 
 
36 (7.8%) 
 
1 (3.2%) 
 
0 
 
Complete  
surgery 
 
492 (99.4%) 
 
458 (99.3%) 
 
31 (100%) 
 
31 (100%) 
Nodal 
metastases at 
primary  
operation 
 
62 (12.5%)       
 
61 (13.2%)        
 
0 
 
1 (33.3%) 
 
Distant 
metastases  at 
diagnosis 
  
1 (0.2%)          
 
0 
 
1 (3.1%)           
 
0 
 
 
 
The majority (94.6%) of the patients underwent near-total thyroidectomy as the 
initial surgical procedure. A selective lymphadenectomy or a modified neck 
dissection was performed for patients with confirmed nodal metastases by diagnosis 
(n=62, 12.5%). Hemithyroidectomy or a resection of varying extent was performed on 
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27 patients, most of whom had a small incidental tumour when operated on for other 
causes. All but three of these tumours were ≤ 1 cm in diameter.  
 
Of the patients, 80% received RRA. The initial treatment dose of 131I varied from 1.11 – 
4.44 GBq (30 – 120 mCi), depending on the uptake. Repeated doses of radio-iodine 
were administered if necessary (77 patients, 15.5%). The completeness of RRA was 
controlled 3-4 months later with DxWBS and TG measurement after withdrawal of L-
T4. 
 
Median follow-up time was 11.6 years (range 5−19 years) in Studies I and IV and 16 
years (range 10 – 24) in Studies II and III. 
 
 
8.2 Use of US and DxWBS in the follow-up (Study I) 
 
For this cohort, we reviewed the records of 2559 follow-up visits. Neck US was 
performed 993 times (38.8% of the follow-up visits). The radiologist proceeded to a 
FNAB in 149 (15.0%) of the examinations. In 28 of the 149 samples (18.8%), the 
cytological finding was considered malignant and in one suspicious (altogether 23 
patients). One patient refused surgery and was referred to external beam radiation 
therapy. In 28 operations, malignancy was confirmed in all but one case (Figure 5). 
Additionally, three neck node operations were scheduled because of a suspicious 
finding in neck US without a suspicious FNAB (not performed in 2 cases, benign in 
one case), and all had a malignant finding at operation. 
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Figure 5. Number and findings of neck ultrasonography (US) and fine-needle 
aspiration biopsy (FNAB) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DxWBS with 131I activity of 0.185 t0 0.37 GBq (5−10 mCi) was performed at 99 follow-
up visits (3.9%) of 75 patients (Figure 6). The scan was positive 43 times in 33 patients 
(44.0%) and negative 56 times. Of 43 positive scans, the uptake was located in the 
neck only in 42 cases (97.7%) and in the lungs and neck in one case (patient with first 
recurrence in the neck only, second recurrence in lungs and neck as indicated by a TG 
on T4 of 14 ug/l). Forty-five (45.5%) of the DxWBS were performed because of 
detectable TG on T4. and the remaining 54 for other causes. These included serum TG 
increasing by 1 μg/l or more compared to the previous visit, without concomitant 
suspicious findings on neck US, and detection of anti-TG antibodies, which made TG 
measurements unreliable. DxWBS was also used in the surveillance of some patients, 
whose primary operation had indicated more aggressive disease (tumour invasion 
into surrounding tissues, suspicion of incomplete surgery, several nodal metastases) 
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No US 
 1566 
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Suspicious US 
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Abnormal US 
3 
Normal US  
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Operation  
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(One refusal) 
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28 
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1 
PAD malignant 
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FNAB benign 
120 
PAD benign 
1 
PAD malignant 
27 
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Figure 6. Use of DxWBS in follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.3 Outcome of 495 patients (Studies I and II) 
 
8.3.1 Disease recurrences 
 
At the time of the first data collection point (median follow-up 11.6 years, range 5-24 
years) in 2002, 44 patients (8.9%) had experienced their first disease recurrence 
(Table 7). All recurrences were located in the neck (Table 7). Median time to disease 
recurrence was 42 (range 12 –214) months. The clear majority of the recurrences, 
93.1%, occurred within 10 years of the diagnosis and 70.7% within the first 5 years.  
Tumour histology was papillary carcinoma in 39 cases and follicular carcinoma in 5 
cases. 
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4. 
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Table 7. Characteristics of patients at diagnosis with and without tumour 
recurrence after 11.6 years (median). 
 
 With recurrence 
n = 44 
Without 
recurrence 
n = 451 
P 
Male sex 
 
12 (27.3%) 68 (15.1%) 0.051 
Age  
(median with range) 
32.5 (6 –83) 40 (15 - 73) 0.0038 
Follicular histology 
 
5 (11.4%) 26 (5.8%) 0.180 
Size in cm 
(median with range) 
2.3 (0.5-5.0) 1.6 (0.1-7.0) 0.019 
Complete surgery 
 
44 (100%) 448 (99.3%) 1.00 
Total thyroidectomy 
(TTE) 
43 (97.7%) 426 (94.4%) 0.498 
Local infiltration in 
primary surgery 
9 (20.5%) 28 (6.2%) 0.0029 
Nodal metastasis in 
primary surgery 
12 (27.3%) 50 (11.1%) 0.0044 
Radio-active 
remnant ablation 
(RRA) given 
 
36 (81.8%) 362 (80.3%) 0.847 
 
 
At the time of renewed data collection (median follow-up 16 years), the cumulative 
number of recurrences had risen to 51 (10.3%). The duration of disease-free period 
after primary treatment, the primary diagnostic tool of the recurrence, localization of 
the recurrence for each patient after a median follow-up of 16 years are presented in 
Table 8. The majority of recurrences were located in the cervical lymph nodes (LN; 
94.1%), were detected with neck US (54.9%) and were confirmed histopathologically. 
The diagnosis of a smaller number of recurrences (31.4%) was confirmed with a 
definite new uptake on diagnostic WBS (Table 7). In one case each, recurrence was 
detected based on increased TG concentration on T4 combined with palpable nodes, 
or a suspect US finding and the appearance of TG antibodies indicated by declining 
recovery. In two cases, increasing concentration of TG without radiological or clinical 
findings provided an indication for therapeutic activity of RAI, and the recurrence 
was confirmed in subsequent RxWBS. 
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Table 8. Disease recurrences 
 
Age at 
diagnosia 
Gender Location of recurrence Diagnostic method  Months to recurrence  
30 Male Cervical LN DxWBS 16 
36 Female Cervical LN US/FNAB 16 
31 Female Cervical LN US/FNAB 18 
53 Female Cervical LN US/FNAB 18 
30 Female Cervical LN US 18 
49 Female Cervical LN US/FNAB 21 
24 Female Cervical LN US 21 
20 Male Cervical LN US/FNAB 21 
16 Female Cervical LN TG + palpation 22 
21 Female Cervical LN US 24 
42 Female Cervical LN DxWBS 24 
18 Female Cervical LN DxWBS 24 
53 Female Cervical LN US/FNAB 25 
27 Male Cervical LN US/FNAB 26 
52 Female Cervical LN DxWBS 27 
42 Female Cervical LN US/FNAB 30 
43 Male Cervical LN US/FNAB 33 
39 Male Cervical LN DxWBS 35 
53 Female Cervical LN DxWBS 35 
27 Male Cervical LN US 36 
33 Female Cervical LN DxWBS 38 
51 Female Cervical LN US/FNAB 48 
40 Female Cervical LN DxWBS 48 
27 Female Cervical LN US/FNAB 52 
25 Female Cervical LN US/FNAB 58 
69 Male Cervical LN DxWBS 58 
26 Female Cervical LN DxWBS 59 
60 Male Cervical LN DxWBS 59 
39 Female Cervical LN US 60 
17 Female Cervical LN DxWBS 60 
20 Female Mediastinal LN TG-on-T4 65 
40 Female Cervical LN US/FNAB 66 
73 Female Cervical LN DxWBS 67 
21 Male Cervical LN US/FNAB 69 
19 Female Cervical LN DxWBS 71 
26 Female Cervical LN US/FNAB 92 
35 Female Cervical LN DxWBS 93 
19 Female Cervical LN TG /US 108 
54 Female Cervical LN TGWBS 108 
34 Male Cervical LN US/FNAB 108 
27 Male Cervical LN US/FNAB 110 
41 Female Cervical LN New TG-AB 113 
43 Female Cervical LN US/FNAB 116 
6 Female Cervical LN US/FNAB 121 
16 Female Cervical LN US/FNAB 131 
19 Female Cervical LN NA 132 
44 Female Cervical LN US/FNAB 144 
32 Male Cervical LN US/FNAB 144 
27 Female Cervical LN US/FNAB 149 
65 Female Cervical LN TG-on-T4 212 
32 Male Cervical LN DxWBS 263 
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8.3.2 Cancer death  
 
At the time of second data analysis, thyroid carcinoma was registered as the cause of 
death in one patient (Statistics Finland), diagnosed with follicular carcinoma at the 
age of 42 years; this patient had diagnosed with a benign follicular adenoma five 
years earlier. The malignant diagnosis was made from a local tumour of 1.2 cm in 
diameter, with no nodal or distant metastases (TNM stage I). A retrospective analysis 
of the primary histological sample revealed capsular invasion.  After total 
thyroidectomy, RRA (3.7 GBq (100mCi)) was administered, post-treatment scan 
(RxWBS) showed no uptake and serum TG on and off L-T4 was undetectable. The 
patient died of thyroid cancer 8 years after the malignant diagnosis.  
 
 
8.4 Prognostic factors  
 
After a median follow-up of 11.6 years (Study I), predictors of recurrence in univariate 
analysis were male sex (p=0.051), age (p=0.0038), tumour size (p=0.019), local 
infiltration (p=0.0029) and nodal metastases (p=0.0044) at primary operation. Also 
MACIS predicted recurrence (p=0.045). In multivariate analysis, independent 
predictors for recurrence were age (p=0.031), male sex (p=0.028) and local 
infiltration at primary operation (p=0.002). 
 
In Study III, with a median follow-up of 16 years, simple logistic analysis of predictive 
factors for disease recurrence revealed that compared with patients without 
recurrence, patients who experienced disease recurrence were younger (p<0.0057), 
more often males (p<0.035) and more often had detectable post-surgical and post-
ablative TG levels (p=0.0251 and p<0.0001, respectively). Patients with recurrence 
also had more nodal metastasis (p=0.0008) and local infiltration (p=0.005) at primary 
surgery. Multiple logistic regression analysis including all statistically significant 
variables revealed that only infiltration at primary surgery (OR 2.66, CI 1.03 – 6.90, 
p=0.04) and post-ablative detectable TG concentrations (OR 3.7, CI 1.71 – 8.05, 
p=0.009) were independent predictors of disease recurrence.   
 
 
 
8.4.1 Serum thyroglobulin (Study II) 
 
Post-surgical TG levels were recorded in 468 cases (94.5%).  After primary total or 
near total thyroidectomy, 250 cases (52.9%) demonstrated post-surgical TG levels 
above the detection limit. Of the 51 patients with disease recurrence, 71% (n=34) had 
a post-operative TG level above the detection limit, as compared with 54% (n=225) of 
the 420 patients without recurrence (p=0.0251). Post-operative TG did not correlate 
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with postoperative TSH concentrations (p=0.056). The post-operative median TSH 
concentrations did not differ between patients with and without recurrence (76 and 
73 mU/l, respectively, p=0.39).  
 
RRA was performed on 414 of the 472 patients who had undergone total or near-
total thyroidectomy (49 patients with subsequent recurrence and 365 without 
recurrence). Post-ablative TG levels were recorded in 401 cases (96.9%) and were 
detectable after the initial RRA therapy in 51 cases (12.7%, median 10.0 g/l, range 1-
500). All patients with detectable TG after initial RRA received repeat doses of RAI 
until TG became undetectable and there was no evidence of disease on post-therapy 
WBS or subsequent DxWBS. Total 131I activity administered varied between 2.2 and 
25.9 GBq (60−700 mCi). After ablation, TG was measurable in 36.4% of patients with 
subsequent recurrence compared with 9.8% of patients without recurrence 
(p<0.0001; Table 2). The corresponding post-ablative median TSH concentrations 
were 44 and 36 mU/l, respectively (p=0.36). Disease recurrence was diagnosed 
significantly more often in patients with detectable TG after initial RRA than in 
patients in whom TG was undetectable (Figure 7, p=0.021). 
 
 
Figure 7. Proportion of recurrence-free patients without (n = 350) and with (n= 51) 
detectable TG after first ablative radio-iodine treatment as a function of time 
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In 79 cases with undetectable TG after RRA, a low recovery (<80%) indicated TG 
antibodies. Nine of these patients subsequently developed disease recurrence. No 
significant difference was present in the prevalence of TG antibodies between 
patients with and without recurrence (p=0.3029).  
 
8.4.2 Prevalence and predictive value of BRAF V600E  
mutation (Study III) 
 
Original tissue samples were retrievable in 26 (57%) of 46 patients who had 
experienced a disease recurrence. Tissue samples from 25 age- and sex-matched 
patients from the same cohort, who had not experienced a recurrence during follow-
up served as controls. Prevalence of the BRAF V600E mutation in the 51 samples 
analyzed, representative of the whole cohort, was 67% (34/51).  
 
The 26 patients with later disease recurrence for whom original tissue samples were 
retrievable did not differ from the 20 patients with disease recurrence for whom 
samples could not be retrieved. No significant differences were observed with regard 
to median age, male gender, primary tumour size, nodal metastasis or local 
infiltration at presentation, time to disease recurrence, detectable TG after RRA , 
number of RRA treatments or mean RRA activity administered (all p=NS). 
 
Prevalence of the BRAF V600E mutation did not differ between patients with and 
without recurrence (65% vs. 68%, p=0.84). Patients with recurrence more often (p= 
0.053) had detectable TG concentrations after RRA than patients without recurrence, 
but did not differ significantly with regard to primary tumour size or nodal metastasis 
in primary surgery. Four patients (15%) with recurrence were characterized by local 
infiltration at presentation compared with none of the patients without recurrence. 
No difference existed between the groups in the proportion of patients receiving 
RRA as part of the initial therapy. Repeated treatment was more often needed in 
patients with later disease recurrence than in patients without, but the difference 
was not significant. Mean initial RRA activity was higher in patients with than 
patients without later disease recurrence, but this difference did not quite reach 
statistical significance [6.9 GBq (189 mCi) vs. 4.3 GBq (116 mCi), p=0.059].   
 
When patients with and without recurrences were combined, of the 34 BRAF 
mutation-positive patients, 50% experienced a disease recurrence compared to 53% of 
BRAF negative patients (p=NS). Median time to disease recurrence was 52 months 
for patients with and 36 months for those without the mutation. This difference did 
not reach statistical significance (p=0.15). Median age, prevalence of male gender 
and tumour size were also similar in both groups. Nodal metastasis (21% vs. 35%) and 
local infiltration (6% vs. 12%) at presentation appeared to be more frequent in BRAF 
mutation-negative patients, but the differences were not significant (p=0.26 and 
p=0.47, respectively). Number of radio-iodine treatments needed initially or mean 
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treatment activity of 131I did not differ between the groups (p=0.67 and p=0.70, 
respectively).  
 
 
8.5 HRQoL after treatment for differentiated thyroid carcinoma  
(Study IV) 
 
HRQoL for 341 patients (48 men, 293 women) aged 23–93 years (mean 52 years) was 
analysed. The majority of patients had papillary tumours (94.5 %), 18 patients (5.3%) 
had follicular carcinoma and one patient had a Hürthle-cell carcinoma. Five patients 
had vocal cord paralysis (0.05%) and six patients prolonged or permanent 
hypoparathyrodism as a surgical complication (0.018%). Eighty-five percent (290 
patients) had received postoperative radio-iodine ablation, 60 of them (20.7%) more 
than one treatment. The daily dose of thyroxine varied from 0.093 mg to 0.400 mg 
(mean 0,171 mg). Median follow-up time from initial surgery was 12.4 (range 5−19.5) 
years. Thirty-three patients (9.6%) had experienced a disease recurrence. 
 
The patients who participated in the HRQoL survey were significantly older than 
those who did not return the questionnaire (52 vs. 42 years; p<0.001). There were no 
statistically significant differences between the two groups in other characteristics 
(gender distribution, number of radio-iodine treatments, disease recurrence, and 
duration of follow-up). 
 
No significant difference between the mean total 15D score of the patients (0.912) 
and that of the age- and gender-standardized general population (0.914) was found.   
With regard to single dimensions, patients were worse off than the general 
population on the dimensions of sleeping, speech and distress (p= 0.001, 0.002 and 
0.012, respectively). With regard to discomfort and symptoms, patients were better 
off than the general population (p<0.001, Figure 8). 
 
Of the different parameters, only the negative marginal effect of age at the time of 
initial treatment reached statistical significance (p<0.001). The data suggest that the 
higher the patients’ age at the time of initial treatment, the lower the HRQoL at the 
time of the survey. Duration of follow-up showed a similar negative marginal effect 
on HRQoL; however, this was not significant. The marginal effect of daily dose of 
thyroxine on HRQoL was positive, but did not quite reach statistical significance 
(p=0.087). The marginal effects of disease recurrence, number of radio-iodine 
treatments and vocal cord paralysis were negative, but again not significant. 
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Figure 8.
 
 
 
For variance in the level values of the dimensions of sleeping, discomfort and 
symptoms, a similar result was obtained. Age at the time of initial treatment was the 
only explanatory variable, with a negative marginal effect that was significant. With 
regard to distress and speech, none of the explanatory variables had a significant 
marginal effect (Table 9).  
 
 
Table 9. 
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Gender (0=female, 1=male) 0.0061 0.6771 
Number of radio-iodine ablations -0.0019 0.8306 
Recurrence (0=no, 1=yes) -0.0087 0.5813 
Daily dose of levothyroxine 0.0027 0.0868 
Duration of follow-up (years) -0.0017 0.1962 
Age at initial treatment (years) -0.0018 <0.0001 
Vocal cord paralysis (0=no, 1=yes) -0.0100 0.8004 
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9  DISCUSSION 
 
9.1 Study population 
 
The increasing prevalence of thyroid cancer can be attributed to the increasing 
incidence of low-risk DTC (Kent et al. 2007, Pacini et al. 2010). This work presents the 
long-term follow-up data of a cohort of 495 patients at low-risk of thyroid cancer-
specific death according to the AJCC-UICC prognostic classification and who were 
disease-free after primary therapy. All patients belong to the favourable TNM stage I 
or II, representing the clear majority of patients in everyday clinical practice. We did 
not include those TNM stage I or II patients who could not be classified as disease-
free after primary therapy: patients with low measurable TG values but no detectable 
disease, patients who would need a tailored and more intensive follow-up.  
 
The cohort is representative of this patient group, with a median age of 40 years and 
a female-to-male ratio of 4:1.  
 
 A considerable number of patients, all uniformly treated and followed up according 
to a uniform strategy and a long follow-up, can be seen as strengths of the study. 
With the presently ongoing shift of treatment paradigms towards a more selective 
use of radio-iodine, this work offers valuable data on long-term outcome of low-risk 
patients treated with thyroidectomy and RRA.  
 
 
9.2 Neck US, DxWBS and TG in follow-up  
 
The cornerstones of the treatment scheme in HUCH have been total or near-total 
thyroidectomy, followed by RRA therapy destroying thyroid remnants and possible 
remaining tumour cells and rendering most patients’ TG levels undetectable on and 
off L-T4 treatment. In surveillance of patients, neck US was frequently used; every 
two years routinely and additionally whenever clinically indicated. TG measurements 
were performed on L-T4 treatment without rhTSH stimulation, with an increase in TG 
to a detectable level being a prompt indication for further investigations. Naturally, 
the treatment and follow-up paradigms have evolved over the years, and at least at 
the beginning of the study period occasional deviations occurred. However, the 
relatively large patient cohort, long follow-up time and routine use of neck US over 
20 years give a solid background to evaluate the surveillance scheme. 
 
In the last ten years, most surveillance protocols have acknowledged the sensitivity 
of neck US in detecting local recurrences. Pacini et al. (2003) found that rhTSH-
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stimulated TG values alone have a sensitivity of 85% for disease detection, rising to 
96.3% when combined with neck US, with a negative predictive value of 99.5%. In a 
series by Mazzaferri and Kloos (2002) of 107 patients with tumours of all stages, nine 
patients with persistent disease were identified with an rhTSH-stimulated serum TG 
level greater than 2 μg/L. However, four of these patients had a detectable, although 
low TG level on L-T4, and in three additional patients neck US located the recurrence 
to the neck (Mazzaferri and Kloos 2002). Accordingly, the surveillance protocol 
would have revealed seven persistent tumours, without rhTSH stimulation tests.  
 
The present study does not support the notion that liberal use of neck US would lead 
to unnecessary FNABs and operations at increased costs and discomfort for the 
patients. Of 993 neck US performed, only 15% led to FNAB, and of 149 FNABs 28 to 
further surgery, with a malignant finding in all but one of the cases. Neck US must 
always be performed by experienced examiners to ensure reliability. It could also be 
argued that using very low TG cut-off levels for further evaluations would lead to a 
large number of additional investigations, with detrimental psychological effects for 
patients. However, in our study, TG on L-T4 was detectable in only 67 patients, and 
further investigations confirmed recurrent tumour in 23 and persistent disease in 
four of these subjects.   
 
When increasingly more small low-risk differentiated cancers are treated with 
surgery only (Vaisman 2011), neck US is more sensitive than any other method in 
detecting a recurrence in follow-up (Durante and Filetti 2011). For patients who do 
not undergo RRA, thyroglobulin assays are difficult to interpret. Neck US also has 
excellent negative predictive value in patients with very low-risk DTC (Durante et al. 
2010). 
 
Sonographic criteria for identifying metastatic involvement of the cervical nodes 
have been well-defined; these include cystic appearance, hyperechoic punctuations, 
loss of hilum, and peripheral vascularization (Leboulleux et al. 2007). As an integral 
part of thyroid cancer follow-up, neck US examination should always be conducted 
by experienced and adequately trained physicians. 
 
In summary, the updated versions of many international guidelines now follow 
principles similar to those studied here.  According to recent ESMO guidelines, at 6–
12 months the follow-up aims to ascertain whether the patient is free of disease and 
is based on physical examination, neck US and basal and rhTSH-stimulated serum TG 
measurement with or without diagnostic WBS (Pacini et al. 2010). The subsequent 
follow-up of patients considered disease-free at the time of their first follow-up 
consists of a physical examination, basal serum TG measurement on LT4 therapy and 
neck US once a year. No other biochemical or morphological tests are indicated 
unless some new suspicion arises during evaluation (Pacini et al. 2010). The American 
Thyroid Associations guidelines recommend neck US at 6 and 12 months after initial 
surgery together with TG measurement to assure remission. Thereafter, neck US is 
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recommended yearly for 3-5 years (Cooper et al. 2006, Cooper et al. 2009). 
Diagnostic WBS in this setting can be omitted (Cooper et al. 2006, Pacini et al. 2010). 
 
 
9.3 Long-term outcome 
 
During the study period 51 patients (10.3%) experienced a recurrence and one patient 
died of thyroid carcinoma.  This concurs with recurrence rates seen in other large 
series and is steadily approaching the 14-15% seen in a 30-year follow-up in a large 
Mayo Clinic cohort (Hay 2007). In another retrospective series of 1528 DTC patients, 
23.5% of patients experienced a recurrence after median follow-up of 16.6 years 
(Mazzaferri and Kloos 2002). In patients treated with thyroidectomy and RAI, the 
number of recurrences was comparable with our series (Mazzaferri and Kloos 2002).  
In a large prospective series with a median follow-up of 6.2 years and patients of all 
TNM stages, the 5-year recurrence rate was 4,2% (Brassard et al. 2011).  
 
The clear majority of the recurrences, 93.1%, occurred within 10 years of the diagnosis 
and 70.7% during the first 5 years. This suggests that 10 years after the initial 
treatment the surveillance could mainly focus on adequate L-T4 therapy and utilize 
TG measurements or neck US at a reduced frequency or when clinically indicated. 
 
Together, these numbers stress that follow-up should indeed aim at early detection 
of disease recurrences, as the majority of these patients are at low-risk of thyroid 
cancer-specific death. For the majority of DTC patients, who also will never 
experience a recurrence, the long-term follow-up should serve to reassure that 
eradication of the tumour is complete.  At the same time, the tests should be able to 
detect persisting or recurrent disease at the earliest possible stage.  Delayed 
detection of local recurrences has been seen to result in significant personal 
suffering and increased mortality, with inoperable tumours that are resistant to 
radiotherapy and chemotherapy. The majority of DTC patients are of working-age, 
which should be factored into the pharmaco-economic considerations of surveillance 
schemes. 
 
Another important objective of continuous surveillance is to maintain adequate 
thyroxine therapy permanently. 
 
 
9.4 Factors prognostic of disease recurrence  
 
After a median follow-up of 11.6 years, univariate analysis indicated that several 
factors, such as age, male gender, tumour size, local infiltration and node metastasis 
in primary surgery and tumour stage according to MACIS predicted recurrent 
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disease. However, in multivariate analysis only age, sex and extracapsular infiltration 
were independent predictors of recurrence.  These factors have been established in 
many large retrospective studies (Hay et al. 1993, Jukkola et al. 2004, Siironen et al. 
2005). In line with the present study, Jukkola et al. (2004) found in a retrospective 
analysis of 499 DTC patients that an accurate definition of risk could be achieved by 
using only two parameters, age (cut-off value 50 years) and extracapsular invasion of 
the thyroid gland. 
 
9.4.1 Prognostic quality of serum thyroglobulin 
 
After a long surveillance (median 16 years), infiltration at primary surgery and 
detectable serum TG concentration off thyroxine after the initial RRA were the only 
independent predictors of a later recurrence in this cohort. Consequently, these 
factors should be taken into account when trying to identify DTC patients at 
increased risk of local recurrence among the larger group of patients at low-risk of 
cancer-specific death. The data imply that in patients treated according to this 
protocol more emphasis should be placed on the follow-up of patients with 
detectable post-ablative TG concentrations, while a lighter follow-up scheme is 
probably indicated in patients with undetectable post-ablative TG. This would also 
help to individually tailor the surveillance scheme and its duration for high-risk 
patients and increase the cost-effectiveness of the surveillance system.  
 
Local infiltration is included in nearly all classification systems for predicting cancer-
specific death, but only a few studies have examined the possible role of post-
surgical or post-ablative TG concentrations on disease outcome (Hall et al. 2003, 
Toubeau et al. 2004, Kim et al. 2005a).  
 
In a study of 268 patients (TNM stage I to III) with a median follow-up of 5.7 years 
(Kim et al. 2005a), the recurrence rate was 13%, and the authors concluded that post-
operative serum TG has a complementary role in predicting disease persistence or 
recurrence. They found a good correlation between post-surgical and post-ablative 
TG concentrations, but no association between post-ablative concentrations and 
recurrence rate (Kim et al. 2005a). In a  5.1-year follow-up study of 212 TNM stage I to 
III patients by Toubeau et al. (2004), recurrence rate was 9% and, in line with the 
present study, post-ablative but not post-surgical TG emerged as a strong predictive 
factor of disease recurrence, in addition to lymph node invasion. Hall et al. (2003) 
studied 212 DTC patients (TNM stages I to IV) for a median of 47 months; 12 % 
experienced recurrence at 11 months. They found that post-surgical TG greater than 
20 pmol/l together with advanced tumour stage were independent predictors of 
disease recurrence (Hall et al. 2003).  
 
Results on recurrence rate after a long-term prospective follow-up of 715 DTC 
patients in complete remission after primary treatment were recently published by 
Brassard et al. (2011). They assessed the predictive value of initial TG levels (after 
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primary treatment) for recurrence and found a negative predictive value of 99% for 
TG both on and off thyroxine therapy. They concluded that initial TG measurement 
allows predicting long-term recurrence with excellent specificity of 86−90% (Brassard 
et al. 2011). Our results support these findings.  
 
The inclusion of stimulated TG concentrations measured 6-12 months after initial 
treatment in the surveillance scheme of DTC patients is strongly emphasized in a 
number of recent guidelines, not only to control the outcome of primary therapy but 
also to guide further surveillance (Cooper et al. 2006, Schlumberger et al. 2004, 
Pacini et al. 2006). The guidelines recommend TG measurements stimulated by 
recombinant human TSH (rhTSH) at 6-12 months after initial RRA. If TG 
concentrations are undetectable, follow-up can thereafter be based on yearly 
evaluation of serum TSH and TG on L-T4 treatment with or without neck US.  
 
In simple logistics analysis, also post-operative TG level correlated with disease 
recurrence. Of the 51 patients with disease recurrence, 71% (n=34) had a post-
operative TG level above the detection limit, as compared with 54% (n=225) of the 
420 patients without recurrence (P=0.0251). In a study comparing low and high 
activity of 131I in ablation, pre-ablative post-surgical levels of TG were predictive of 
success of RRA (Mäenpää et al. 2008). 
 
Taken together, the data suggest that the response to initial treatment predicts 
recurrence-free survival and should guide follow-up of DTC patients. TG is a valuable 
tool in the setting of total thyroidectomy followed by RRA. Prophylactic neck 
compartment dissection has been suggested to be a surrogate for post-operative 
ablation. The advantages and disadvantages of each procedure remain to be 
compared and discussed.  
 
The use of high-quality serum TG analysis can improve the cost-effectiveness of 
management and follow-up of DTC patients. Serum TG assay sensitivity has greatly 
improved in the last decades, lowering the analytical sensitivity from approximately 
0.8 ng/ml to 0.01 ng/ml. This together with the reliability of the assays may result in 
less need for TSH stimulation in a setting of negative neck US. The main problem 
with this approach is the unrequested follow-up procedures in patients with minimal 
measurable basal TG levels (0.2–0.5 ng/ml) who, before the availability of the second-
generation TG assay, were classified as disease-free with undetectable TG.  
 
 
9.5 BRAF V600E mutation in low-risk PTC 
 
Since it was first described in thyroid cancer, the BRAF V600E mutation has proven to 
be the most common genetic event in the onset of PTC, responsible for around 45% 
of cases.  The mutation occurs exclusively in PTC or PTC-derived anaplastic tumours, 
but not in FTC or other types of thyroid tumours. This suggests a unique pathogenic 
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role of this mutation in the development of PTC. Up-regulation of VEGF, MMPS, 
resulting in tumour angiogenesis and invasion, has been observed, as has aberrant 
gene methylation, resulting in abnormal silencing of tumour suppressor genes (Xing 
2007). Pathways leading to observed loss of radio-iodine avidity remain to be 
identified.  
 
The relationship between BRAF V600E mutation and outcome of PTC has been 
extensively investigated (Xing et al. 2005, Xing 2007). Most studies have 
demonstrated a significant association between the mutation and the conventional 
high-risk clinicopathological characteristics of PTC  (e.g. older age, advanced TNM 
stages, lymph node metastasis, distant metastasis, recurrence and persistence of 
disease) (Xing 2007). Of note, most of these prognostic factors have been validated 
with disease-specific death and not recurrence as the outcome. Some studies have 
demonstrated a significant association with tumour recurrence as well (Xing et al. 
2005, Kebebew et al. 2007). These studies included patients of all TNM stages and 
have not clearly differentiated between recurrent and persistent disease.  
 
In the present study, no correlation was seen between BRAF mutation and disease 
recurrence or time to recurrence. Furthermore, BRAF mutation was not associated 
with larger tumour size, invasion or nodal metastasis at presentation. A limitation of 
our study was that only 57% of the original tumour tissue samples of patients with 
recurrent disease were retrieved for determination of BRAF V600E status. To assure 
that these patients would be representative of all patients experiencing disease 
recurrence, we compared their characteristics with patients experiencing disease 
recurrence but with unknown BRAF status. No significant differences emerged 
between these groups in any of the characteristics. Another limitation is that for five 
patients with recurrence, BRAF mutation was determined from a nodal metastasis, 
as primary tumour tissue was unattainable. However, a close correlation between 
BRAF status in paired primary and recurrent PTC has been demonstrated (Barollo et 
al. 2010). 
 
The results indicate that although common in Finnish PTC patients, BRAF mutation 
does not serve as a prognostic marker for later recurrence in a low-risk patient 
population treated with thyroidectomy and RRA. The question of whether a 
correlation would have been present had the patients not received active primary 
treatment with RRA, remains unanswered. 
 
BRAF mutations have also been linked to loss of avidity for RAI. In a study of 50 DTC 
patients with recurrent disease, Barollo and colleagues (2010) found that 94% of 
BRAF V600E-positive recurrent patients were 131I-negative. We wanted to test the 
association between BRAF mutation and sensitivity to primary RRA, but found no 
differences in the mean activity of RAI needed for ablation in this small patient 
cohort.   
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Mutated BRAF may in the future also be a therapeutic target for PTC. A number of 
BRAF inhibitors have been investigated as potential new agents for targeted 
therapies. One BRAF inhibitor (vemurafenib) has been authorized for use in BRAF 
mutant melanoma in 2011 and studies are ongoing in papillary thyroid cancer 
(www.clinicaltrials.gov). Other inhibitors of the MAPK pathway are also being 
investigated.  
 
 
9.6 Health-related quality of life  
 
Studies focusing on HRQoL of cured DTC patients are few (Botella-Carretero et al. 
2003, Tagay et al. 2005, Crevenna et al. 2003, Giusti et al. 2005, Dagan et al. 2004, 
Schultz et al., Tan et al., Eustatia-Rutten et al. 2006, Hoftijzer et al. 2008).  
 
Tagay and colleagues (2005) compared HRQoL in 130 hospitalized patients during 4-
weeks of L-T4 withdrawal and in 100 outpatients on suppressive thyroxine therapy to 
that of a German reference population (n= 2914). Botella-Carretero et al. (2003) 
compared 18 DTC patients, both in the euthyroid state and during suppressive doses 
of L-T4, with 18 healthy controls using four validated HRQoL questionnaires. Mild or 
moderate impairment on several dimensions (sleep, mental health, energy, 
emotional, social functioning, total score) correlated with subclinical 
hyperthyroidism. In the biochemically euthyroid state, the results were more 
comparable with those of the healthy controls.  Among 24 DTC patients with a 
disease history of at least 10 years, Eustatia-Rutten et al. (2006) compared the effect 
of continued TSH-suppressive thyroxine therapy (n= 12) with that of restored 
euthyroidism (n= 12) gained over 6 months. The results were compared with age-
adjusted reference values. At baseline, patients demonstrated only minor clinically 
insignificant impairments in HRQoL on four validated questionnaires (SF-36, Mfi-20, 
HADS, SRS). The data indicate that HRQoL may not be impaired in DTC patients in 
long-term follow-up, even during TSH suppressive thyroxine therapy (Eustatia-Rutten 
et al. 2006).  
 
Hoftijzer et al. (2008) assessed HRQoL with validated health-related questionnaires 
in 153 cured DTC patients and compared the results with those of 113 healthy 
controls, selected by the patients themselves, as well as with 336 age- and gender-
matched controls from other local studies. Duration of disease-free period varied 
considerably (0.3 – 41.8 years). Quality of life was impaired in DTC patients relative to 
the two control groups in 11 and 13 of the 16 subscales, respectively. The HRQoL 
parameters were not influenced by serum TSH levels, but were inversely affected by 
duration of cure.  Although the representativeness of the control groups can be 
challenged, the authors concluded, that in DTC patients quality of life was restored 
after 12-20 years of cure (Hoftijzer et al.). 
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In our study, we focused on patients who represent a clear majority in everyday 
clinical practice. The median duration of follow-up was 11.6 years. We used the 15D 
multidimensional validated generic instrument (Sintonen 2001) instead of cancer- or 
other disease-specific questionnaires to assess HRQoL to be able to compare the 
results with those of the general population.  The instrument is highly sensitive 
(Saarni et al. 2006, Moock and Kohlmann 2008) and combines the advantages of a 
profile and single index instrument. The control population was large, consisting of a 
sample of 6001 age- and gender-standardized Finnish subjects.  
 
In this study, overall HRQoL index score did not differ from that of the general 
population and the slight numerical difference observed has no clinical importance. 
Of the single dimensions, DTC patients reported a significant impairment in sleep, 
speech and distress. Sleep disturbances could be attributed to exogenous subclinical 
hyperthyroidism, while the disturbances in speech are more difficult to explain. The 
study cohort comprised only five cases of vocal cord paralysis (0.015%). One possible 
explanation is xerostomia in DTC patients, due to radio-iodine therapy. However, 
with regard to discomfort and symptoms, DTC patients were significantly better off 
than the general population. The findings are somewhat unexpected and difficult to 
explain. One explanation might be that DTC patients benefit from the once-yearly 
contact provided by the surveillance scheme, as opposed to the general population. 
Another explanation may lie in the impact of subclinical hyperthyroidism on 
subjective well-being. Within the DTC patient group, a statistically significant inverse 
effect of age at the time of initial treatment on overall HRQoL was observe; no other 
significant effects of the parameters included in the model (gender, number of radio-
iodine ablations, recurrence, daily dose of thyroxine, duration of follow-up and vocal 
paralysis) were noted.  
 
In long-term follow-up, cured TNM stage I and II DTC patients did not suffer from 
overall impaired HRQoL compared with the general population. DTC patients 
demonstrate an age-related decline in HRQoL, which is compatible with that seen in 
the general population.  
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10 SUMMARY AND CONCLUSIONS 
 
 
 
The major findings of this work are as follows: 
 
 In this uniformly treated cohort of low-risk TNM stage I or II DTC patients (n=495) 
with median follow-up of 16 years, 51 patients (10.3%) experienced disease 
recurrence, a finding comparable with other large international series. The clear 
majority of recurrences occurred in the first 10 years after primary treatment. The 
finding may be useful in modifying follow-up protocols for low-risk DTC.  
 Predictors of disease recurrence in a low-risk patient group after long-term follow-up 
are tumour infiltration at diagnosis and post-ablative positive thyroglobulin levels. 
These findings add to the growing body of evidence that response to primary 
therapy is a significant prognostic factor. This can be used to guide surveillance. 
 BRAF V600E mutation is a common finding, but does not appear to correlate with 
disease recurrence after treatment with total thyroidectomy and RRA among low-
risk patients.  
 Health-related quality of life after extensive primary treatment of low-risk DTC and 
long-term follow-up remains comparable with that of an age-adjusted general 
population.  
 The surveillance scheme in use for low-risk DTC patients at HUCH for 20 years has 
proven efficient and safe after long-term follow-up. The same principles have now 
been adapted also by many international centres. 
 Neck US combined with serum TG measurement on thyroxine therapy is a reliable 
and efficient way of monitoring DTC patients who have undergone near-total 
thyroidectomy followed by radio-iodine ablation and are disease-free after primary 
therapy. For intermediate-risk and high-risk patients, surveillance must be tailored.  
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